Document:

Biologics Distribution Agreement

  
 Exhibit 10.7

  
 BIOLOGICS DISTRIBUTION AGREEMENT 

 
 THIS DISTRIBUTION AGREEMENT (“Agreement”), dated as of
February 27, 2004, is made and executed by and between ACCENTIA, INC., a Florida corporation (“Accentia”) and McKESSON CORPORATION, a Delaware corporation (“McKesson”) based on the following facts and
understandings: 
  
 WHEREAS, Accentia is a vertically integrated
specialty pharmaceutical company engaged in the identification, acquisition, development and distribution of biologic products; 
  
 WHEREAS, Accentia and McKesson entered into a Forbearance Agreement dated as of December 9, 2003 and an Assumption of Debt and Security Agreement dated as
of December 31, 2003 (the “Assumption Agreement”). The Recitals set forth in said agreements are incorporated herein by reference, provided that to the extent there is any irreconcilable inconsistency between the Recitals in the
Forbearance Agreement and the Recitals in the Assumption of Debt and Security Agreement, the Recitals in the Assumption of Debt and Security Agreement shall control because it is the more recent of the two documents; 
  
 WHEREAS, Accentia desires to grant and convey and McKesson desires to acquire
the exclusive rights to distribute all current and future biologic products developed or acquired by Accentia; 
  
 NOW THEREFORE, for fair and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Accentia and McKesson hereby agree as
follows: 
  
 SECTION 1 Definitions: Interpretation

  
 (a) All capitalized terms used in this Agreement and not
otherwise defined herein shall have the meanings assigned to them in the Assumption of Debt and Security Agreement. 
  
 (b) As used in this Agreement (including the Preamble hereof), the following terms shall have the following meanings: 
  
 “Accentia” means Accentia, Inc, a Florida
corporation together with all Majority Owned Subsidiaries of Accentia. On the date of this Agreement, the following are majority owned subsidiaries of Accentia: Teamm Pharmaceuticals, Inc, Analytica, Inc and Biovest International, Inc. 

 
 “Biologic Products” means products such
as monoclonal antibodies, peptides, antigens for autologous cancer vaccines such as for non-Hodgkins lymphoma and renal cell carcinoma, cytokines, and viruses produced by mammalian cell culture techniques under an FDA license for commercialization.

  

 -Signature Page- 

 “Person” means an individual, corporation, partnership, joint venture,
trust, unincorporated organization, governmental agency or authority, or any other entity of whatever nature. 
  
 “Net Revenue” means the gross proceeds received by Accentia from the sale of Biologic Products for use in the Territory
less all returns, rebates, discounts, advertising allowances, Cost of Distribution and product cost. 
  
 “Territory” means the United States, Mexico, and Canada. 
  
 “FDA” means the U. S. Food and Drug Administration. 
  
 “Cost of Distribution” means all expenses,
including but not limited to materials, direct labor, indirect labor and overhead determined in accordance with generally accepted accounting principals consistently applied that are paid or incurred by McKesson, or its affiliated entities, in
providing services in connection with the distribution of Biologic Products under this Agreement. Any dispute regarding Cost of Distribution shall be resolved by mutual agreement of the parties and failing mutual agreement by arbitration in
accordance with the Rules of the American Arbitration Association. 
  
 “Distribution Services” means any and all services relating to the distribution of Biologic Products performed by McKesson under this Agreement. 
  
 “Majority Owned Subsidiary of Accentia”
means a subsidiary in which Accentia currently owns or hereafter acquires fifty-one per cent (51%) or more of the outstanding capital stock or equity interests (including membership interests in a limited liability company or partnership interests
in a partnership or joint venture, etc.). 
  
 “Biologic Product Owned By Accentia” means any Biologic Product which is owned by Accentia by virtue of purchase, assignment, license or which is otherwise controlled by Accentia under agreement or joint venture.

  
 SECTION 2 Exclusive Distributor 
  
 A. Distributor. Accentia hereby appoints McKesson and McKesson hereby
agrees to serve as the exclusive distributor in the Territory for all Biologic Products Owned by Accentia during the Term of this Agreement. The forgoing appointment includes Biologic Products Owned by Accentia as of the date of this Agreement and
all Biologic Products subsequently acquired by Accentia during the term of this Agreement. (“Distribution Rights”). 
  
 B. Refundable Deposit. McKesson shall remit to Accentia a non-interest bearing refundable deposit for the Distribution Rights in the amount of
three million dollars ($3,000,000) (“Refundable Deposit”) upon execution of this Agreement. The Refundable Deposit shall be returned by Accentia to McKesson upon termination of this Agreement in accordance with Section 4 below. Upon
termination, once McKesson receives repayment of the Refundable Deposit, McKesson will cease to have the exclusive distribution rights granted under this Agreement. So long as the Refundable Deposit is not repaid to McKesson in full, McKesson shall
continue to have the 

  

 2 

 
exclusive right to distribute the Biologic Products, but shall be under no obligation to undertake any distribution efforts, though McKesson will continue to
have a right to the Distributor Fee payable under this Agreement and to receive reimbursement for any Costs of Distribution. The retention of the exclusive right to distribute pending payment in full of the Refundable Deposit shall be in addition
to, and not in lieu of, any other rights and remedies McKesson may have under this Agreement, any other agreement with Accentia or its affiliates and, applicable law. 
  
 SECTION 3 Fees 
  
 A. Distributor Fee. Accentia shall pay McKesson a monthly fee equal to five percent (5%) of all Net Revenue, as defined in Section 1 hereof, from
the sale of all Biologic Products Owned By Accentia (“Distributor Fee”). The Distributor Fee shall be paid within twenty (20) days following the end of each calendar month and shall be accompanied by an accounting prepared by Accentia of
all Net Revenue. 
  
 B. Reimbursement of Cost of
Distribution. In addition to the Distributor Fee, Accentia shall reimburse McKesson for all Costs of Distribution, as defined in Section 1, hereof. McKesson shall monthly provide a detail invoice of the Cost of Distribution and Accentia shall
pay all approved Cost of Distribution within twenty days of said Invoice. 
  
 C. Disposition of Ownership of Biologic Product. In the event Accentia sells, licenses or otherwise disposes of its ownership of any Biologic Product (“Disposition of Biologic Product”), Accentia
shall pay McKesson a termination payment equal to five percent (5%) of the net consideration received at any time by Accentia from the sale, license or disposition of the Biologic Product for the Territory. The termination payment shall be paid in
the same form and at the same time as received by Accentia from the disposition of the Biologic Product. 
  
 D. Disposition of Majority Owned Subsidiary. In the event any Majority Owned Subsidiary of Accentia which owns a Biologic Product then being
distributed by McKesson ceases to be a Majority Owned Subsidiary of Accentia, Accentia shall pay to McKesson a termination payment equal to five percent (5%) of the lesser of: (i) 100% of the net consideration received by Accentia for the
subsidiary; or (ii) the appraisal value of all of said subsidiary’s Biologic Products for the Territory. The appraisal shall be performed by an appraiser mutually selected by McKesson and Accentia and if the parties can not mutually agree upon
the selection of an appraiser, McKesson and Accentia shall each appoint a separate appraiser, the two of whom shall mutually select a third appraiser. The third appraiser shall perform the appraisal. Notwithstanding the forgoing, no termination
payment shall be payable upon the disposition of a Majority Owned Subsidiary of Accentia provided the Subsidiary agrees to continue the appointment of McKesson as the exclusive Distributor of all Biologic Products of said subsidiary in the Territory
in form and substance acceptable to McKesson. 
  

 3 

 SECTION 4 Term and Termination. 
  
 This Agreement shall continue until the first to occur of: (i) mutual written termination executed by McKesson and Accentia;
(ii) written notice of material breach which is not cured within thirty (30) days of said written notice of breach, provided the non-breaching party requests termination either in such written notice of material breach or in a later writing; (iii)
180 days after Accentia’s receipt of written communication from McKesson that McKesson wishes, in its sole and absolute discretion, to terminate the Distribution Agreement, and (iv) repurchase of the Distribution Rights by Accentia prior to FDA
approval of the first product for a cash payment equal to the greater of (a) two times the amount of the Refundable Deposit or (b) 3% of the value of the shareholder’s equity of Accentia at the time of termination (the “Term”).
In the event of termination pursuant to the preceding subsection (iv): 
  
 (a) In order to effectuate such termination, Accentia shall give McKesson not fewer than 30 calendar days’ notice of it’s intention to repurchase the Distribution Rights pursuant to this Section 4(iv); 
  
 (b) In the interim, the parties shall negotiate in good faith the value of
Accentia’s shareholder’s equity. 
  
 (c) If at the time
notice of intent to repurchase is given, Accentia’s stock is publicly traded, the value of Accentia’s shareholders equity shall be based on the highest share price of Accentia’s common stock at any time commencing from the date that
is 15 calendar days prior to the earlier of the giving of the notice of the intent to repurchase, and the date upon which there is a public disclosure that Accentia intends to repurchase the Distribution Rights, through the date of the closing of
Accentia’s repurchase of the Distribution Rights from McKesson. 
  
 (d) If at the time notice of intent to repurchase is given, Accentia’s stock is not publicly traded, the value of Accentia’s shareholders equity shall be determined by mutual agreement. 
  
 (e) Any dispute regarding the value of the shareholder equity shall be
resolved by mutual agreement of the parties and failing mutual agreement by arbitration in accordance with the Rules of the American Arbitration Association. 
  
 In the event the Distribution Agreement is terminated pursuant to Section 4(iv) of this Agreement, the payment of the repurchase price under this Agreement shall be in
lieu of the return of the Refundable Deposit. 
  
 SECTION 5
Amendments to Forbearance and Assumption Agreements 
  
 A.
Net Sales Based Fee The parties hereby amend the Forbearance Agreement and the Assumption Agreement to eliminate any obligation on the part of Accentia or any Majority Owned Subsidiary of Accentia to pay a Net Sales based Fee based on any
Biologic Products Owned by Accentia other than the Distributor Fees and the reimbursement of the Cost of Distribution as provided herein. 
  
 B. Definition of “Obligations.” The term “Obligations” as defined in the Assumption Agreement shall be amended to add the
payment and performance by 

  

 4 

 
Accentia of all of its obligations set forth in this Agreement. It is the expectation and intention that all assets of Accentia shall secure the payment and
performance by Accentia of this Agreement and that the grant of such liens and security interests shall be and hereby is reaffirmed as securing all the “Obligations” as defined in the Assumption Agreement and as such term is amended in
this Distribution Agreement. 
  
 SECTION 6 Representations and
Warranties 
  
 A. Accentia represents and warrants to McKesson
that: 
  
 (a) Accentia is a corporation duly organized, validly
existing and in good standing under the laws of the state of Florida and has all requisite power and authority , to execute, deliver and perform its obligations under this Agreement. 
  
 (b) The execution, delivery and performance by Accentia of this Agreement have been duly authorized by all necessary action
of Accentia, and this Agreement constitutes the legal, valid and binding obligation of Accentia. 
  
 (c) No authorization, consent, approval, license, exemption of, or filing or registration with, any governmental authority or agency, or approval or
consent of any other Person, is required for the due execution, delivery or performance by Accentia of this Agreement. 
  
 (d) Distribution of Biologic Products hereunder is subject to and conditioned upon the following: (i) terms and provisions of this Agreement and (ii)
applicable rules, regulations and requirements, including but not limited to the rules, regulations and requirements of the FDA, regarding the distribution, handling, manufacture, sale or use or otherwise applicable to the Biologic Products.

  
 B. McKesson represents and warrants to Accentia that:

  
 (a) McKesson is a corporation duly organized, validly existing
and in good standing under the laws of the state of Delaware and has all requisite power and authority to execute, deliver and perform its obligations under this Agreement. 
  
 (b) The execution, delivery and performance by McKesson of this Agreement have been duly authorized by all necessary action
and this Agreement constitutes the legal, valid and binding obligation of McKesson. 
  
 (c) Distribution of Biologic products hereunder is subject to and conditioned upon the following: (i) terms and provisions of this Agreement and (ii) applicable rules, regulations and requirements, including but not
limited to the rules, regulations and requirements of the FDA, regarding the distribution, handling, manufacture, sale or use or otherwise applicable to the Biologic Products. 
  

 5 

 SECTION 7 Covenants 
  
 (a) Accentia shall deliver to McKesson not later than the 30th day after each fiscal quarter during the term hereof consolidated income statements, balance sheets and statements of cash flow, each prepared in accordance
with GAAP. 
  
 (b) Accentia shall deliver to McKesson a copy of
any and all reports, statements, business plans, and other documentation, which it (or any of it Majority Owned Subsidiaries) provides to any of its (or their) shareholders and such deliveries to McKesson shall be contemporaneous with the deliveries
to such shareholders. 
  
 (c) Accentia shall appear in and defend
any action, suit or proceeding which may affect to a material extent its title to, or right or interest in, or McKesson’s rights to distribute the Biologic Products for use in the Territory and shall do and perform all reasonable acts that may
be necessary and appropriate to maintain, preserve and protect the Biologic Products. In the event Accentia shall fail to appear in and defend andy action, suit or proceeding as required in this subsection 7(c), or if such appearance or defense in
the reasonable belief of McKesson is inadequate, then McKesson’ may undertake such appearance and/or defense, and hire professionals in connection therewith, and Accentia shall indemnify and hold McKesson harmless for the cost thereof.

  
 (d) Accentia shall comply in all material respects with all
laws, regulations and ordinances, and all policies of insurance, relating in a material way to the possession, operation, maintenance and control of the Biologic Products. 
  
 (e) Accentia agrees to defend, indemnify and hold McKesson harmless against any claims, liability or expense whatsoever,
including counsel fees, and compensatory, multiple, exemplary and punitive damages, and fines, alleged to have arisen through the purchase, use, consumption or recall of the Biologic Products, whether involving a defect in the product, its labeling
or packaging, unless and until it is proven to be due to McKesson’s negligent handling of the products after shipment by Accentia. Accentia agrees that the laws of California shall apply to any such proceeding, and agrees to submit to the
jurisdiction of the Superior Court of the State of California for the County of San Francisco in any action brought pursuant to this paragraph 7(e). Accentia expressly waves all claims of lack of personal jurisdiction and inconvenient forum in any
such proceeding brought before that court. 
  
 (f) Before
requesting McKesson to perform any services hereunder, Accentia shall carry and maintain in full force and effect, at its own expense and with financially sound and reputable insurance companies, general liability insurance in an amount of not less
than five million dollars ($5,000,000). Such policy shall provide broad form vendors coverage naming McKesson Corporation and its subsidiaries as additional insureds and also provide blanket contractual liability insuring paragraph 7 (e) hereof.
Insurance shall be primary and collectible regardless of whether other valid and collectible insurance is available to McKesson and its subsidiaries. Such insurance 

  

 6 

 
shall also provide for written 30 day notice to McKesson of cancellation and list parent company and all subsidiaries/divisions of Accentia, if any, covered
by the policy. Accentia shall cause its insurance agent or company to furnish to McKesson annually a certificate of insurance evidencing the insurance required hereunder to the following address: 
  
 McKesson Corporation 
 One Post Street 
 San Francisco, CA 94104-5296 
 Attn: Business Information Services 
  
 (g) Accentia shall permit McKesson at all reasonable times to inspect its books and records for the specific and limited purpose of verifying Accentia’s calculation of Net Revenue. 
  
 SECTION 8 Notices 
  
 All notices or other communications hereunder shall be in writing (including
by facsimile transmission) and mailed, sent or delivered to the respective parties hereto at or to their respective addresses or facsimile numbers set forth below their names on the signature pages hereof, or at or to such other address or facsimile
number as shall be designated by any party in a written notice to the other parties hereto. All such notices and other communications shall be deemed to be delivered when a record (within the meaning of the UCC) has been (i) delivered by hand; (ii)
sent by mail upon the earlier of the date of receipt or five business days after deposit in the mail, first class (or air mail as to communications sent to or from the United States); or (iii) sent by facsimile transmission. 
  
 SECTION 9 No Waiver; Cumulative Remedies 
  
 No failure on the part of either party hereto to exercise, and no delay in
exercising, any right, remedy, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, remedy, power or privilege preclude any other or further exercise thereof or the exercise of
any other right, remedy, power or privilege. The rights and remedies under this Agreement are cumulative and not exclusive of any rights, remedies, powers and privileges that may otherwise be available. 
  
 SECTION 10 Binding Effect 
  
 This Agreement shall be binding upon, inure to the benefit of and be
enforceable by Accentia and McKesson and their respective successors and assigns and shall bind any Person who becomes bound as a debtor to this Agreement. No party may assign, transfer, hypothecate or otherwise convey its rights, benefits,
obligations or duties hereunder without the prior express written consent of the other 

  

 7 

 
parties hereto. Any such purported assignment, transfer, hypothecation or other conveyance without the prior express written consent of the other parties
shall be void. 
  
 SECTION 11 Governing Law This Agreement
shall be governed by, and construed in accordance with, the law of the State of Florida, except as required by mandatory provisions of law 
  
 SECTION 12 Entire Agreement: Amendment This Agreement contains the entire agreement of the parties with respect to the subject matter hereof and
shall not be amended except by the written agreement of the parties. 
  
 SECTION 13 Severability 
  
 Whenever possible,
each provision of this Agreement shall be interpreted in such manner as to be effective and valid under all applicable laws and regulations. If, however, any provision of this Agreement shall be prohibited by or invalid under any such law or
regulation in any jurisdiction, it shall, as to such jurisdiction, be deemed modified to conform to the minimum requirements of such law or regulation, or, if for any reason it is not deemed so modified, it shall be ineffective and invalid only to
the extent of such prohibition or invalidity without affecting the remaining provisions of this Agreement, or the validity or effectiveness of such provision in any other jurisdiction. 
  
 SECTION 14 Counterparts 
  
 This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed
shall be deemed to be an original and all of which taken together shall constitute but one and the same agreement. 
  

 8 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement, as of the date first above
written. 
  

			
	 ACCENTIA, INC.

		
	 By:
	 	 /s/ Frank O’ Donnell

	 Print Name: Frank O’ Donnell, M.D.

	 Title Chairman & CEO

	
	 MCKESSON CORPORATION

		
	 By:
	 	 /s/ Ana Schrank

	 Print Name: Ana Schrank

	 Title: VP, Financial Services

  

 -Signature Page-Cooperative Research and Development Agreement

  
 Exhibit 10.12

  
 PUBLIC HEALTH SERVICE 
  
 COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT 
  
 This Cooperative Research and Development Agreement, hereinafter referred to as the
“CRADA,” consists of this Cover Page, an attached Agreement, and various Appendices referenced in the Agreement. This Cover Page serves to identify the Parties to this CRADA: 
  
 (1) the following Bureau(s), Institute(s), Center(s) or Division(s) of the National Institutes of Health (“NIH”),
the Food and Drug Administration (“FDA”), and the Centers for Disease Control and Prevention (“CDC”): 
  
 The National Cancer Institute (“NCI”), hereinafter singly or collectively referred to as the Public Health Service (“PHS”); and

  
 (2) Biovest International, which has offices at 540 Sylvan
Avenue, Englewood Cliffs, NJ 07632-3022, hereinafter referred to as the “Collaborator.” 
  

					
	 	  	Page 1 of 11	  	CONFIDENTIAL

 COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT 
  
 Article 1. Introduction 
  
 This Cooperative Research and Development Agreement (CRADA) between PHS and the Collaborator will be effective when signed
by all Parties. The research and development activities which will be undertaken by each of the Parties in the course of this CRADA are detailed in the Research Plan (RP) which is attached as Appendix A. The funding and staffing commitments of the
Parties are set forth in Appendix B. Any exceptions or changes to the CRADA are set forth in Appendix C. This CRADA is made under the authority of the Federal Technology Transfer Act, 15 U.S.C. 3710a and is governed by its terms. 
  
 Article 2. Definitions 
  
 As used in this CRADA, the following terms shall have the indicated meanings: 
  

	2.1	“Affiliate” means any corporation or other business entity controlled by, controlling, or under common control with Collaborator. For this purpose,
“control” means direct or indirect beneficial ownership of at least fifty (50) percent of the voting stock or at least fifty (50) percent interest in the income of such corporation or other business. 

  

	2.2	“Cooperative Research and Development Agreement” or “CRADA” means this Agreement, entered into by PHS pursuant to the Federal Technology Transfer Act of
1986, as amended, 15 U.S.C. 3710a et seq. and Executive Order 12591 of October 10. 1987. 

  

	2.3	“Government” means the Government of the United States as represented through the PHS agency that is a Party to this agreement. 

  

	2.4	“IP” means intellectual property. 

  

	2.5	“Invention” means any invention or discovery which is or may be patentable or otherwise protected under title 35, United States Code, or any novel variety or plant
which is or may be protectable under the Plant Variety Protection Act (7 U.S.C. 2321 et seq.). 

  

	2.6	“Principal Investigator(s)” or “PIs” means the persons designated respectively by the Parties to this CRADA who will be responsible for the
scientific and technical conduct of the RP. 

  

	2.7	“Proprietary/Confidential Information” means confidential scientific, business, or financial information provided that such information does not include:

  

	 	2.7.1	  information that is publicly known or available from other sources who are not under a confidentiality obligation to the source of the information; 

 

	 	2.7.2 	information which has been made available by its owners to others without a confidentiality obligation; 

  

	 	2.7.3 	information which is already known by or available to the receiving Party without a confidentiality obligation; or 

  

					
	 	 	Page 2 of 11	 	CONFIDENTIAL

	 	2.7.4 	information which relates to potential hazards or cautionary warnings associated with the production, handling or use of the subject matter of the Research Plan of this CRADA.

  

	2.8	“Research Materials” means all tangible materials other than Subject Data first produced in the performance of this CRADA. 

 

	2.9	“Research Plan” or “RP” means the statement in Appendix A of the respective research and development commitments of the Parties to this CRADA.

  

	2.10	“Subject Invention” means any Invention of the Parties, conceived or first actually reduced to practice in the performance of the Research Plan of this
CRADA. 

  

	2.11	“Subject Data” means all recorded information first produced in the performance of this CRADA by the Parties. 

  
 Article 3. Cooperative Research 
  

	3.1	Principal Investigators. PHS research work under this CRADA will be performed by the PHS laboratory identified in the RP, and the PHS Principal Investigator (PI) designated
in the RP will be responsible for the scientific and technical conduct of this project on behalf of PHS. Also designated in the RP is the Collaborator PI who will be responsible for the scientific and technical conduct of this project on behalf of
the Collaborator. 

  

	3.2	Research Plan Change. The RP may be modified by mutual written consent of the Principal Investigators. Substantial changes in the scope of the RP will be treated as
amendments under Article 13.6. 

  
 Article 4. Reports

  

	4.1	Interim Reports. The Parties shall exchange formal written interim progress reports on a schedule agreed to by the PIs, but at least within twelve (12) months after this
CRADA becomes effective and at least within every twelve (12) months thereafter. Such reports shall set forth the technical progress made, identifying such problems as may have been encountered and establishing goals and objectives requiring further
effort, any modifications to the Research Plan pursuant to Article 3.2, and identify Subject Inventions pursuant to Article 6.1. 

  

	4.2	Final Reports. The Parties shall exchange final reports of their results within four (4) months after completing the projects described in the RP or after the expiration or
termination of this CRADA. 

  
 Article 5. Financial and Staffing
Obligations 
  

	5.1	PHS and Collaborator Contributions. The contributions of the Parties, including payment schedules, if applicable, are set forth in Appendix B. PHS shall not be obligated to
perform any of the research specified herein or to take any other action required by this CRADA if the funding is not provided as set forth in Appendix B. PHS shall return excess funds to the Collaborator when it sends its final fiscal report
pursuant to Article 5.2, except for staffing support pursuant to Article 10.3. Collaborator acknowledges that the U.S. Government will have the authority to retain and expend any excess funds for up to one (1) year subsequent to the expiration or
termination of the CRADA to cover any costs incurred during the term of the CRADA in undertaking the work set forth in the RP. 

  

					
	 	 	Page 3 of 11	 	CONFIDENTIAL

	5.2	Accounting Records. PHS shall maintain separate and distinct current accounts, records, and other evidence supporting all its obligations under this CRADA. and shall provide
the Collaborator a final fiscal report pursuant to Article 4.2. 

  

	5.3	Capital Equipment. Equipment purchased by PHS with funds provided by the Collaborator shall be the property of PHS. All capital equipment provided under this CRADA by one
party for the use of another Party remains the property of the providing Party unless other disposition is mutually agreed upon by in writing by the Parties. If title to this equipment remains with the providing Party, that Party is responsible for
maintenance of the equipment and the costs of its transportation to and from the site where it will be used. 

  
 Article 6. Patent Applications 
  

	6.1	Reporting. The Parties shall promptly report to each other in writing each Subject Invention and any patent applications filed thereon resulting from the research conducted
under this CRADA that is reported to them by their respective employees. Each Party shall report all Subject Inventions to the other Party in sufficient detail to determine inventorship. Such reports shall be treated as Proprietary/Confidential
Information in accordance with Article 8.4. 

  

	6.2	Filing of Patent Applications. Each party shall be responsible for filing patent or other IP applications in a timely manner and at its own expense and after consultation
with the other Party. The Parties will consult and mutually determine a filing strategy for jointly-owned subject inventions. 

  

	6.3	Patent Expenses. The expenses attendant to the filing of patent or other IP applications generally shall be paid by the Parly filing such application. If an exclusive license
to any Subject Invention is granted to the Collaborator, the Collaborator shall be responsible for all past and future out-of-pocket expenses in connection with the preparation, filing, prosecution and maintenance of any applications claiming such
exclusively-licensed inventions and any patents or other IP grants that may issue on such applications. The Collaborator may waive its exclusive license rights on any application, patent or other IP grant at any time, and incur no subsequent
compensation obligation for that application, patent or IP grant. 

  

	6.4	Prosecution of Intellectual Property Applications. Within one month of receipt or filing, each Party shall provide the other Party with copies of the applications and all
documents received from or filed with the relevant patent or other IP office in connection with the prosecution of such applications. Each Party shall also provide the other Party with the power to inspect and make copies of all documents retained
in the patent or other IP application files by the applicable patent or other IP office. Where licensing is contemplated by Collaborator, the Parties agree to consult with each other with respect to the prosecution of applications for PHS Subject
Inventions and joint Subject Inventions. If the Parties agree that Collaborator shall file and prosecute IP applications on joint Subject Inventions, then Collaborator agrees to grant PHS an associate power of attorney (or its equivalent) on such IP
applications. 

  
 Article 7. Licensing 
  

	7.1	 Option for Commercialization License. With respect to Government IP rights to any Subject Invention not made solely by the Collaborator’s employees for
which a patent or other IP application is filed, PHS hereby grants to the Collaborator an exclusive option to elect an exclusive or nonexclusive commercialization license, which is substantially in the form of the appropriate model PHS
license agreement. This option does not apply to Subject Inventions conceived prior to the effective date of this CRADA that are reduced to practice under this CRADA, if prior to that reduction to practice, PHS has 

  

					
	 	 	Page 4 of 11	 	CONFIDENTIAL

	 	 
filed a patent application on the invention and has licensed it or offered to license it to a third party. The terms of the license will fairly reflect the
nature of the invention, the relative contributions of the Parties to the invention and the CRADA, the risks incurred by the Collaborator and the costs of subsequent research and development needed to bring the invention to the marketplace. The
field of use of the license will be commensurate with the scope of the RP. 

  

	7.2	Exercise of License Option. The option of Article 7.1 must be exercised by written notice mailed within three (3) months after either (I) Collaborator receives written notice from
PHS that the patent or other IP application has been filed; or (ii) the date Collaborator files such IP application. Exercise of this option by the Collaborator initiates a negotiation period that expires nine (9) months after the exercise of the
option. If the last proposal by the Collaborator has not been responded to in writing by PHS within this nine (9) month period, the negotiation period shall be extended to expire one (1) month after PHS so responds, during which month the
Collaborator may accept in writing the final license proposal of PHS. In the absence of such acceptance, or an extension of the time limits by PHS, PHS will be free to license such IP rights to others. In the event that the Collaborator elects the
option for an exclusive license, but no such license is executed during the negotiation period, PHS agrees not to make an offer for an exclusive license on more favorable terms to a third party for a period of six (6) months without first offering
Collaborator those more favorable terms. These times may be extended at the sole discretion of PHS upon good cause shown in writing by the Collaborator. 

  

	7.3	License for PHS Employee Inventions and Joint Inventions. Pursuant to 15 U.S.C.’ 3710a(b)(l)(A), for Subject Inventions made under this CRADA by a PHS employee(s) or jointly by
such employee(s) and employees of the Collaborator and licensed pursuant to the option of Article 7.1, the Collaborator grants to the Government a nonexclusive, nontransferable, irrevocable, paid-up license to practice the invention or have the
invention practiced throughout the world by or on behalf of the Government. In the exercise of such license, the Government shall not publicly disclose trade secrets or commercial or financial information that is privileged or confidential within
the meaning of 5 U.S.C. 552(b)(4) or which would be considered as such if it had been obtained from a non-Federal party. 

  

	7.4	License in Collaborator Inventions. Pursuant to 15 U.S.C.’ 3710a(b)(2), for inventions made solely by Collaborator employees under this CRADA, the Collaborator grants to the
Government a nonexclusive, nontransferable, irrevocable, paid-up license to practice the invention or have the invention practiced throughout the world by or on behalf of the Government for research or other Government purposes.

  

	7.5	Third Party License. Pursuant to 15 U.S.C.’ 3710a(b)(l)(B), if PHS grants an exclusive license to a Subject Invention made wholly by PHS employees or jointly with a
Collaborator under this CRADA, the Government shall retain the right to require the Collaborator to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to use the invention in Collaborator=s licensed field
of use on terms that are reasonable under the circumstances; or if the Collaborator fails to grant such a license, to grant the license itself. The exercise of such rights by the Government shall only be in exceptional circumstances and only if the
Government determines (I) the action is necessary to meet health or safety needs that are not reasonably satisfied by Collaborator, (ii) the action is necessary to meet requirements for public use specified by Federal regulations, and such
requirements are not reasonably satisfied by the Collaborator; or (iii) the Collaborator has failed to comply with an agreement containing provisions described in 15 U.S.C. 3710a(c)(4)(B). The determination made by the Government under this Article
is subject to administrative appeal and judicial review under 35 U.S.C. 203(2). 

  

	7.6	 Joint Inventions Not Exclusively Licensed. In the event that the Collaborator does not acquire an exclusive commercialization license to IP rights in all fields in
joint Subject Inventions then each Party 

  

					
	 	 	Page 5 of 11	 	CONFIDENTIAL

	 	 
shall have the right to use the joint Subject Invention and to license its use to others in all fields not exclusively licensed to Collaborator. The Parties
may agree to a joint licensing approach for such IP rights. 

  
 Article 8. Proprietary Rights and Publication 
  

	8.1	Right of Access. PHS and the Collaborator agree to exchange all Subject Data produced in the course of research under this CRADA. Research Materials will be shared equally by
the Parties to the CRADA unless other disposition is agreed to by the Parties. All Parties to this CRADA will be free to utilize Subject Data and Research Materials for their own purposes, consistent with their obligations under this CRADA.

  

	8.2	Ownership of Subject Data and Research Materials. Subject to the sharing requirements of Paragraph 8.1 and the regulatory filing requirements of Paragraph 8.3, the producing
Party will retain ownership of and title to all Subject Inventions, all Subject Data and all Research Materials produced solely by their investigators. Jointly developed Subject Inventions, Subject Data and Research Materials will be jointly owned.

  

	8.3	Dissemination of Subject Data and Research Materials. To the extent permitted by law, the Collaborator and PHS agree to use reasonable efforts to keep Subject Data and
Research Materials confidential until published or until corresponding patent applications are filed. Any information that would identify human subjects of research or patients will always be maintained confidentially. To the extent permitted by
law, the Collaborator shall have the exclusive right to use any and all CRADA Subject Data in and for any regulatory filing by or on behalf of Collaborator, except that PHS shall have the exclusive right to use Subject Data for that purpose, and
authorize others to do so, if the CRADA is terminated or if Collaborator abandons its commercialization efforts. Collaborator acknowledges the basic research mission of the PHS, and agrees that after publication, PHS may make unpatented research
materials arising out of this CRADA available to third parties for further research. 

  

	8.4	Proprietary/Confidential Information. Each Party agrees to limit its disclosure of Proprietary/Confidential Information to the amount necessary to carry out the Research Plan
of this CRADA, and shall place a confidentiality notice on all such information. Confidential oral communications shall be reduced to writing within 30 days by the disclosing Party. Each Party receiving Proprietary/Confidential Information agrees
that any information so designated shall be used by it only for the purposes described in the attached Research Plan. Any Party may object to the designation of information as Proprietary/Confidential Information by another Party. Subject Data and
Research Materials developed solely by the Collaborator may be designated as Proprietary/Confidential Information when they are wholly separable from the Subject Data and Research Materials developed jointly with PHS investigators, and advance
designation of such data and material categories is set forth in the RP. The exchange of other confidential information, e.g., patient-identifying data, should be similarly limited and treated. Jointly developed Subject Data and Research Material
derived from the Research Plan may be disclosed by Collaborator to a third party under a confidentiality agreement for the purpose of possible sublicensing pursuant to the Licensing Agreement and subject to Article 8.7. 

  

	8.5	 Protection of Proprietary/Confidential Information. Proprietary/Confidential Information shall not be disclosed, copied, reproduced or otherwise made
available to any other person or entity without the consent of the owning Party except as required under court order or the Freedom of Information Act (5 U.S.C. ‘ 552). Each Party agrees to use its best efforts to maintain the
confidentiality of Proprietary/Confidential Information. Each Party agrees that the other Party is not liable for the disclosure of Proprietary/Confidential Information which, after notice to and consultation with the concerned Party, the 

  

					
	 	 	Page 6 of 11	 	CONFIDENTIAL

	 	 
other Party in possession of the Proprietary/Confidential Information determines may not be lawfully withheld, provided the concerned Party has been given an
opportunity to seek a court order to enjoin disclosure. 

  

	8.6	Duration of Confidentiality Obligation. The obligation to maintain the confidentiality of Proprietary/Confidential Information shall expire at the earlier of the date when
the information is no longer Proprietary Information as defined in Article 2.7 or three (3) years after the expiration or termination date of this CRADA. The Collaborator may request an extension to this term when necessary to protect
Proprietary/Confidential Information relating to products not yet commercialized. 

  

	8.7	Publication. The Parties are encouraged to make publicly available the results of their research. Before either Party submits a paper or abstract for publication or otherwise
intends to publicly disclose information about a Subject Invention, Subject Data or Research Materials, the other Party shall be provided thirty (30) days to review the proposed publication or disclosure to assure that Proprietary/Confidential
Information is protected. The publication or other disclosure shall be delayed for up to thirty (30) additional days upon written request by any Party as necessary to preserve U.S. or foreign patent or other IP rights. 

  
 Article 9. Representations and Warranties 
  

	9.1	Representations and Warranties of PHS. PHS hereby represents and warrants to the Collaborator that the official signing this CRADA has authority to do so.

  

	9.2	Representations and Warranties of the Collaborator. 

  
 (a) The Collaborator hereby represents and warrants to PHS that the Collaborator has the requisite power and authority to enter into this CRADA and to
perform according to its terms, and that the Collaborator’s official signing this CRADA has authority to do so. The Collaborator further represents that it is financially able to satisfy any funding commitments made in Appendix B. 

 
 (b) The Collaborator certifies that the statements herein are true,
complete, and accurate to the best of its knowledge. The Collaborator is aware that any false, fictitious, or fraudulent statements or claims may subject it to criminal, civil, or administrative penalties. 
  
 Article 10. Termination 
  

	10.1	Termination By Mutual Consent. PHS and the Collaborator may terminate this CRADA, or portions thereof, at any time by mutual written consent. In such event the Parties shall
specify the disposition of all property, inventions, patent or other IP applications and other results of work accomplished or in progress, arising from or performed under this CRADA, all in accordance with the rights granted to the Parties under
the terms of this Agreement. 

  

	10.2	Unilateral Termination. Either PHS or the Collaborator may unilaterally terminate this entire CRADA at any time by giving written notice at least thirty (30) days prior to
the desired termination date, and any rights accrued in property, patents or other IP rights shall be disposed of as provided in paragraph 10.1, except that PHS may, at its option, retain funds transferred to PHS prior to unilateral termination by
Collaborator for use in completing the Research Plan solely or with another partner. 

  

					
	 	 	Page 7 of 11	 	CONFIDENTIAL

	10.3	Staffing. If this CRADA is mutually or unilaterally terminated prior to its expiration, funds will nevertheless remain available to PHS for continuing any staffing commitment
made by the Collaborator pursuant to Article 5.1 above and Appendix B, if applicable, for a period of six (6) months after such termination. If there are insufficient funds to cover this expense, the Collaborator agrees to pay the difference.

  

	10.4	New Commitments. No Party shall make new commitments related to this CRADA after a mutual termination or notice of a unilateral termination and shall, to the extent
feasible, cancel all outstanding commitments and contracts by the termination date. 

  

	10.5	Termination Costs. Concurrently with the exchange of final reports pursuant to Articles 4.2 and 5.2, PHS shall submit to the Collaborator for payment a statement of all costs
incurred prior to the date of termination and for all reasonable termination costs including the cost of returning Collaborator property or removal of abandoned property, for which Collaborator shall be responsible. 

  
 Article 11. Disputes 
  

	11.1	Settlement. Any dispute arising under this CRADA which is not disposed of by agreement of the Principal Investigators shall be submitted jointly to the signatories of this
CRADA. If the signatories are unable to jointly resolve the dispute within thirty (30) days after notification thereof, the Assistant Secretary for Health (or his/her designee or successor) shall propose a resolution. Nothing in this Article shall
prevent any Party from pursuing any additional administrative remedies that may be available and, after exhaustion of such administrative remedies, pursuing all available judicial remedies. 

  

	11.2	Continuation of Work. Pending the resolution of any dispute or claim pursuant to this Article, the Parties agree that performance of all obligations shall be pursued
diligently in accordance with the direction of the PHS signatory. 

  
 Article 12. Liability 
  

	12.1	Property. The U.S. Government shall not be responsible for damages to any Collaborator property provided to PHS, where Collaborator retains title to the property, or any
property acquired by Collaborator for its own use pursuant to this CRADA. 

  

	12.2	NO WARRANTIES. EXCEPT AS SPECIFICALLY STATED IN ARTICLE 9, THE PARTIES MAKE NO EXPRESS OR IMPLIED WARRANTY AS TO ANY MATTER WHATSOEVER, INCLUDING THE CONDITIONS OF THE
RESEARCH OR ANY INVENTION OR PRODUCT, WHETHER TANGIBLE OR INTANGIBLE, MADE, OR DEVELOPED UNDER THIS CRADA, OR THE OWNERSHIP, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE RESEARCH OR ANY INVENTION OR PRODUCT. 

 

	12.3	Indemnification. The Collaborator agrees to hold the U.S. Government harmless and to indemnify the Government for all liabilities, demands, damages, expenses and losses
arising out of the use by the Collaborator for any purpose of the Subject Data, Research Materials and/or Subject Inventions produced in whole or part by PHS employees under this CRADA, unless due to the negligence or willful misconduct of PHS, its
employees, or agents. The Collaborator shall be liable for any claims or damages it incurs in connection with this CRADA. PHS has no authority to indemnify the Collaborator. 

  

					
	 	 	Page 8 of 11	 	CONFIDENTIAL

	12.4	Force Majeure. Neither Party shall be liable for any unforeseeable event beyond its reasonable control not caused by the fault or negligence of such Party, which causes such
Party to be unable to perform its obligations under this CRADA, and which it has been unable to overcome by the exercise of due diligence. In the event of the occurrence of such a force majeure event, the Party unable to perform shall
promptly notify the other Party. It shall further use its best efforts to resume performance as quickly as possible and shall suspend performance only for such period of time as is necessary as a result of the force majeure event.

  
 Article 13. Miscellaneous 
  

	13.1	Governing Law. The construction, validity, performance and effect of this CRADA shall be governed by Federal law, as applied by the Federal Courts in the District of
Columbia. Federal law and regulations will preempt any conflicting or inconsistent provisions in this CRADA. 

  

	13.2	Entire Agreement. This CRADA constitutes the entire agreement between the Parties concerning the subject matter of this CRADA and supersedes any prior understanding or
written or oral agreement. 

  

	13.3	Headings. Titles and headings of the articles and subarticles of this CRADA are for convenient reference only, do not form a part of this CRADA, and shall in no way affect
its interpretation. The PHS component that is the Party for all purposes of this CRADA is the Bureau(s), Institute(s), Center(s) or Division(s) listed on the Cover Page herein. 

  

	13.4	Waivers. None of the provisions of this CRADA shall be considered waived by any Party unless such waiver is given in writing to the other Party. The failure of a Party to
insist upon strict performance of any of the terms and conditions hereof, or failure or delay to exercise any rights provided herein or by law, shall not be deemed a waiver of any rights of any Party. 

  

	13.5	Severability. The illegality or invalidity of any provisions of this CRADA shall not impair, affect, or invalidate the other provisions of this CRADA.

  

	13.6	Amendments. If either Party desires a modification to this CRADA, the Parties shall, upon reasonable notice of the proposed modification or extension by the Party desiring
the change, confer in good faith to determine the desirability of such modification or extension. Such modification shall not be effective until a written amendment is signed by the signatories to this CRADA or by their representatives duly
authorized to execute such amendment. 

  

	13.7	Assignment. Neither this CRADA nor any rights or obligations of any Party hereunder shall be assigned or otherwise transferred by either Party without the prior written
consent of the other Party. 

  

	13.8	Notices. All notices pertaining to or required by this CRADA shall be in writing and shall be signed by an authorized representative and shall be delivered by hand or sent by
certified mail, return receipt requested, with postage prepaid, to the addresses indicated on the signature page for each Party. Notices regarding the exercise of license options shall be made pursuant to Article 7.2. Any Party may change such
address by notice given to the other Party in the manner set forth above. 

  

	13.9	Independent Contractors. The relationship of the Parties to this CRADA is that of independent contractors and not agents of each other or joint venturers or partners. Each
Party shall maintain sole and exclusive control over its personnel and operations. Collaborator employees who will be working at PHS facilities may be asked to sign a Guest Researcher or Special Volunteer Agreement appropriately modified in view of
the terms of this CRADA. 

  

					
	 	 	Page 9 of 11	 	CONFIDENTIAL

	13.10 	Use of Name or Endorsements. By entering into this CRADA. PHS does not directly or indirectly endorse any product or service provided, or to be provided, whether directly or
indirectly related to either this CRADA or to any patent or other IP license or agreement which implements this CRADA by its successors, assignees, or licensees. The Collaborator shall not in any way state or imply that this CRADA is an endorsement
of any such product or service by the U.S. Government or any of its organizational units or employees. Collaborator issued press releases that reference or rely upon the work of PHS under this CRADA shall be made available to PHS at least 7 days
prior to publication for review and comment. 

  

	13.11 	Exceptions to this CRADA. Any exceptions or modifications to this CRADA that are agreed to by the Panics prior to their execution of this CRADA are set forth in Appendix
C. 

  

	13.12 	Reasonable Consent. Whenever a Party’s consent or permission is required under this CRADA, such consent or permission shall not be unreasonably withheld.

  
 Article 14. Duration of Agreement 
  

	14.1	Duration. It is mutually recognized that the duration of this project cannot be rigidly defined in advance, and that the contemplated time periods for various phases of the
RP are only good faith guidelines subject to adjustment by mutual agreement to fit circumstances as the RP proceeds. In no case will the term of this CRADA extend beyond the term indicated in the RP unless it is revised in accordance with Article
13.6. 

  

	14.2	Survivability. The provisions of Articles 4.2, 5-8, 10.3-10.5, 11.1, 12.2-12.4, 13.1, 13.10 and 14.2 shall survive the termination of this CRADA. 

  
 SIGNATURES BEGIN ON THE NEXT PAGE 
  

					
	 	 	Page 10 of 11	 	CONFIDENTIAL

					
	 FOR PHS:
	 	 	 	 
			
	 /s/ Alan Ralsor
	 	 	 	 8/30/01

	 Alan Ralsor, M.D.
	 	 	 	 Date

	 Deputy Director, NCI
	 	 	 	 

  
 Mailing Address for Notices:

  
 National Cancer Institute-Frederick 
 Technology Transfer Branch 
 1003 West Seventh Street, Suite 502 

Frederick MD 21701 
 Phone: 301-846-5465 
 FAX: 301-846-6820 
  

					
	 FOR THE COLLABORATOR:
	 	 	 	 
			
	 /s/ Christopher Kyriakides
	 	 	 	  
	 	 	 	 	 Date

	 	 	 	 

  
 Mailing Address for Notices:

  
 Biovest International, Inc. 
 8500 Evergreen Boulevard 
 Minneapolis MN 55433 
 763-786-0302 
 763-786-0915 
  

					
	 	 	Page 11 of 11	 	CONFIDENTIAL

  
 APPENDIX A 

 
 RESEARCH PLAN 
  
 Clinical Development of Hybridoma-Based Idiotypic Vaccines for

 Treatment of Follicular B-Cell Lymphoma 
  

NCI Principal Investigator(s) 
 Larry W.
Kwak, M.D., Ph.D. 
 Center for Cancer Research (CCR) 
 National Cancer Institute (NCI) 
  
 Collaborator Principal Investigator(s) 
 Christopher Kyriakides, M.D., FAAPMR 
 Chief Executive Officer 
 Biovest International, Inc. 
  
 Term of CRADA 
 Eight (8) years from the date of the final CRADA signature. 
  
 A Letter of Intent (LOI) for this CRADA was executed 
 by and between the Parties on
January 9, 2001. 
 An Extension to the LOI was executed by and between 
 the Parties on June 25, 2001 
  

					
	 	 	A-1	 	CONFIDENTIAL

 GOALS OF THIS CRADA 
  
 The goal of this project is to develop an efficacious hybridoma-based idiotype vaccine to produce long-term disease-free survival in follicular B-cell lymphoma patients
who have attained a complete clinical response from chemotherapy and to compile data required to support a Biological License Application (BLA) to the U.S. Food and Drug Administration (FDA) for hybridoma-based idiotype follicular B-cell lymphoma
vaccine. 
  
 The Center for Cancer Research (CCR), National Cancer Institute (NCI)
and Collaborator shall work together toward the successful development of the hybridoma-based idiotype vaccine as a safe and effective novel anti-cancer treatment for follicular B-cell lymphoma. The CCR will work closely with Collaborator to obtain
and evaluate the clinical data that may be required to allow Collaborator to obtain regulatory approval by the FDA. Collaborator will provide expertise in the development, formulation and Good Manufacturing Practice (GMP) production of the vaccine.
Additionally, CCR will work with Collaborator in the ongoing clinical trial planned under this CRADA as well as all regulatory aspects and the BLA filings necessary for Collaborator to obtain marketing approval. 
  
 The scope of this CRADA includes the development of the processes required for large-scale
GMP production of adequate numbers of GMP-produced and formulated idiotype vaccines-to complete the clinical development of this treatment for follicular B-Cell lymphoma. This vaccine strategy involves the use of an immunological adjuvant,
granulocyte-macrophage colony-stimulating factor (GM-CSF), which is currently being provided to NCI for this study under a Clinical Trial Agreement with Immunex. 
  
 BACKGROUND  
  
 INTRODUCTION 
  
 Current Treatment of Indolent Follicular Lymphomas 
 The indolent follicular lymphomas (FL) are follicular small-cleaved cell
(FSC) and follicular mixed lymphoma (FM). Stage I and II patients comprise only 10% to 15% of all cases of follicular lymphomas and are best managed with radiation therapy. Eighty-five percent of patients with follicular lymphomas present with stage
III or IV disease. The optimal management of these patients remains controversial and has generally followed two divergent approaches (1, 2). An aggressive approach, which has included radiation therapy, combination chemotherapy, or combined
modality therapy; and a conservative approach that involves no initial treatment followed by a single-agent chemotherapy or involved-field radiotherapy when required (3, 4). Most forms of systemic therapy have the capacity to produce high complete
response rates. However, they have failed to produce long-term disease-free survival or to prolong overall survival; thus, it has become clear that the vast majority of patients with this disease will relapse and die of their lymphoma, despite its
usually indolent course. 
  
 Technology
Summary 
  
 The development of a vaccine against human malignancies has been
a long-sought goal, which has yet to be achieved. Many of the efforts toward this end have been frustrated by the lack of identification of a tumor-specific antigen which would allow tumor cells to be distinguished from normal cells. Conceptually,
such an antigen could be used as a vaccine to induce the host’s immune system to reject cells bearing that antigen. 
  

					
	 	 	A-2	 	CONFIDENTIAL

 Immunoglobulin (Ig) molecules are composed of heavy and light chains, which possess highly specific variable regions at
their amino termini. The variable regions of heavy and light chains combine to form the unique antigen-recognition site of the Ig protein. These variable regions contain determinants that can themselves be recognized as antigens, or
idiotypes. B-cell malignancies are composed of clonal proliferations of cells synthesizing a single antibody molecule with unique variable regions in the heavy and light chains. B-cell lymphomas are neoplasms of mature resting and reactive
lymphocytes, which generally express synthesized Ig on the cell surface. The idiotypic determinants of the surface Ig of a B-cell lymphoma can thus serve as a tumor-specific marker for the malignant clone. 
  
 Studies in experimental animals, as well as in man, have demonstrated the utility of the Ig
idiotype as a tumor-specific antigen (5, 6). Lynch and Eisen were the first to demonstrate that active immunization against idiotypic determinants on malignant B cells could produce resistance to tumor growth, and this phenomenon of idiotype tumor
resistance has been reproduced subsequently in a number of syngeneic experimental tumor models, as well as specific anti-tumor therapy against established tumors (7-16). These results, taken together, provided the rationale for testing autologous
tumor-derived idiotypic surface Ig (Id) as a therapeutic “vaccine” against human B-cell lymphoma. 
  
 Summary of Previous Clinical Studies Sponsored by NCI 
  
 Phase 1 Clinical Trial. 
  
 Kwak et al. first immunized human patients with B-cell lymphoma with autologous Id protein (17). The Id-keyhole limpet hemocyanin (Id-KLH) was emulsified in a Pluronic polymer-based adjuvant vehicle formulation. Ultimately, approximately 40
patients were treated on this protocol. Because the study population was heterogeneous, it was not designed to answer the question of anti-tumor efficacy. Rather, this first study assessed the question of immunogenicity; i.e., is it even possible to
immunize a patient against a self-tumor antigen? In this context, this study was important, because it demonstrated that patients with B-cell lymphoma could be induced to make primarily idiotype-specific antibody responses, but with little evidence
for T-cell immunity. 
  
 Improving the potency of the Id-KLH
Vaccine. 
  
 At the NCI, the objective of Id vaccine
development has been to further optimize the immunogenicity of this vaccine. To this end, NCI focused on the use of novel immunological adjuvants, which were 1), more potent and 2) more effective in the induction of cell-mediated immune responses,
particularly CD8+ T-cells, compared with the pluronic polymer-based adjuvant used in the pilot study. 
  
 As a preclinical aim, Kwak et al. utilized a murine B cell tumor as a model system in which to screen promising immunological adjuvants. A number of these
included cytokines, and among these, GM-CSF emerged as a promising adjuvant for idiotypic Ig antigen (18). 
  
 The results demonstrated that the augmented survival benefit afforded by immunization with relevant Id-KLH alone could significantly enhanced by the
addition of GM-CSF at either the 100 or 10,000 unit dose. A curious but reproducible observation was the loss of this protective effect at a higher dose of GM-CSF of 50,000 units. These data suggest that GM-CSF may have a potent adjuvant effect
in vivo for Id-KLH antigen, especially at relatively low doses. 
  

					
	 	 	A-3	 	CONFIDENTIAL

 Furthermore, T-cell subset depletion experiments demonstrated that effector CD8+ T-cells were required
for anti-tumor immunity. 
  
 Phase 2 Clinical Trial.

  
 Based on the findings of this preclinical study, the NCI
sponsored a Phase 2 clinical study to evaluate the ability of this new idiotype vaccine to elicit tumor-specific T-cell immunity, as measured by the ability of patient T cells to specifically lyse their own tumor cells in vitro, and to exert
antitumor effects as measured by the elimination of t(14; 18)-bearing cells from the peripheral blood of uniformly treated FL patients in first CR (complete remission). Patients in this study were previously untreated and received a uniform
chemotherapy regimen, PACE; Prednisone, Adriamycin, Cytoxan, and Etoposide. (modified ProMACE without methotrexate). By design, therefore, they comprised a very homogeneous patient population in a minimal residual disease state. Of 35 patients, 23
(66%) achieved CR by standard clinical criteria. One of the patients was lost to analysis because of early relapse within six months, and two were excluded because a vaccine could not be made. This left a total study group of 20 patients in CR. Six
to 15 months after completion of chemotherapy, these 20 patients were treated with a series of five monthly vaccinations with autologous FL Ig protein (0.5 mg) conjugated to KLH, together with local granulocyte-macrophage colony-stimulating factor
(GM-CSF, 100 or 500 mcg/m2) subcutaneously (19). 
  
 Eighteen of
20 patients remain in continuous, first complete remission (median: 42+ months from completion of chemotherapy, range: 28+ to 53+). UPN 9 and 14 relapsed at 15 and 7 months after completion of vaccine therapy, respectively. UPN 9 had never cleared
the t(14; 18)-bearing cells from the peripheral blood; UPN 14 did not have the MBR rearrangement and thus, molecular CR status could not be established. 
  
 The rationale for a pivotal, randomized trial, which is the subject of this CRADA is thus based on three independent results from this completed Phase 2
study: (1) tumor-specific CD8+ T-cell responses (cytotoxicity against autologous FL targets and cytokine production) were seen in 17 of 20 (85%) vaccinated patients, (2) 8 of 11 (73%) patients sampled after completion of vaccination converted to PCR
negative and have maintained both PCR negativity and clinical CR, and (3) with a median follow-up of 36+ months after completion of chemotherapy (range 22+ to 47+ months), 18 of 20 (90%) patients remain in continuous clinical CR. 
  
 Taken together, these data suggest that idiotype vaccination can elicit a
tumor-specific response that is associated with clearance of residual tumor cells from the blood in the majority of patients with FL. It remains to be determined whether molecular CR is associated with prolonged disease-free survival. However, this
systematic analysis of molecular response rate provides the first evidence for an anti-tumor effect of vaccination. Finally, this study established GM-CSF as an essential component of the vaccine strategy, particularly for induction of CD8+ T-cell
responses. 
  
 CCR, NCI 
  
 Dr. Kwak and his group pioneered the first human studies of vaccines for B-cell
malignancies. Dr Kwak’s group has a broad range of scientific and clinical interests spanning tumor immunology, adoptive T cell therapy, and management of lymphomas and myelomas. 
  

					
	 	 	A-4	 	CONFIDENTIAL

 Specific work in his laboratory is focused on studies of immunobiology and immunotherapy of hematological malignancies.
The laboratory’s principal objective is to obtain conclusive proof for the cancer vaccine concept; i.e., simply that it is possible to induce an immune response against a self protein, which is inherently poorly immunogenic, in human cancer
patients. The goals for vaccine development are: (1) to increase the potency of vaccine formulations, and (2) to develop formulations which are more effective in activating the cellular arm of the immune response. The working hypothesis is that
achieving the eventual goal of demonstrating clinical efficacy will depend on the ability of vaccines to elicit sustained, potent cell-mediated responses. 
  
 The current clinical trial of Id vaccination in previously untreated patients with follicular lymphomas initiated by the laboratory, which is the subject of this CRADA,
features a new formulation of the prototype Id-KLH conjugate vaccine using GM-CSF as a potent immunological adjuvant. CD8+ T cell responses, capable of lysing autologous tumor targets, and molecular remissions have been observed in the vast majority
of vaccinated patients. 
  
 BIOVEST INTERNATIONAL INC. 

 
 INTRODUCTION 
  
 The proprietary technology of Biovest (hollow fiber bioreactor instrumentation) that will be applied under this CRADA utilizes a patented
process that optimizes fluid flow dynamics within perfused bioreactors to maintain high cell densities and continuously harvest secreted protein for extended periods of time. An experienced team of mechanical, electrical, software and biochemical
engineers was established at Biovest to develop this technology. As a result of these efforts, the company gained significant expertise in the large-scale application of cGMP mammalian cell culture, which has subsequently been applied to a wide
variety of cell lines for hollow fiber bioreactor production of recombinant or fusion based proteins. Combined with this existing expertise, a cGMP process will be developed that will be designed to facilitate commercial application of
patient-specific vaccines. 
  
 Biovest’s cell culture expertise was
recognized when the National Center for Research Resources, NIH, awarded the National Cell Culture Center to Biovest. This research resource facility was awarded to Biovest in 1990 through a competitive five-year Cooperative Agreement Award, which
has been renewed twice, currently funded through September 2005 This resource was created to provide the biomedical research community with subsidized access to professional large-scale cell culture services. During that time, Biovest has received
hundreds of cell lines from academic investigators within many major research institutions in the United States, for the purpose of large-scale production. The majority of these lines are hybridoma, transfected or chimeric lines, created for the
production of immunoglobulin. 
  
 In addition, for the past ten years, Biovest has
provided contract services to biotechnology and pharmaceutical companies for use in clinical (cGMP) applications, produced in isolation suites within Biovest’s manufacturing facility. For the vast majority of these cell lines, automated hollow
fiber bioreactor instrumentation is utilized for protein production. Biovest instrumentation, combined with years of process development experience for high-cell density perfusion culture, is one principal advantage of Biovest’s contract
laboratory. This ability to modify hardware and understand the biochemical aspects of high-density culture has allowed us to develop successfully many processes unique to large-scale culture, which are typically incorporated into cGMP manufacture of
the final product. Currently, a documentation system exists that addresses cGMP production requirements for 

  

					
	 	 	A-5	 	CONFIDENTIAL

 
numerous specialized cell lines and processes with hollow fiber bioreactor technology in a multi-use facility. . 
  
 Similar to cGMP cell culture procedures, the existing instrumentation was developed as a
Class I medical device, suitable for clinical application. This experience will be an important asset to the development and large-scale manufacture of instrumentation that can be applied to vaccine production. 
  
 Biovest International, Inc. (formerly Cellex Biosciences) is a leading manufacturer of hollow
fiber bioreactor instrumentation and contract production services worldwide. In 1984, the corporation began development of instrumentation that automated the culture of mammalian cells on a large scale. Subsequently, the company utilized this hollow
fiber bioreactor technology to create a cGMP production process that accommodates economic production of large amounts of specific cell-secreted protein (e.g. monoclonal antibodies) from numerous cell lines within one facility. During the past two
decades, Biovest has developed a range of hollow fiber bioreactor instruments to address production at the research level through large-scale pharmaceutical needs. This patented technology is now widely accepted by numerous biotechnology and
pharmaceutical companies throughout the world. As a result, Biovest, with perfusion cell culture methodology (hollow fiber bioreactor), offers a well-defined cGMP approach to large-scale commercial production of clinical and pharmaceutical grade
proteins. 
  
 In December 1999, Biovest was awarded a contract with NCI to produce
idiotype (antibody) as crude supernatant from heteromyeloma patient cell lines, created in Dr. Kwak’s laboratory. This idiotype was subsequently used to create the Id-keyhole limpet hemocyanin (Id-KLH) lymphoma vaccine for study in an ongoing
Phase 3 clinical trial, which is the subject of this CRADA. Creation of this vaccine is extremely labor intensive and Biovest, along with Dr. Kwak, recognized that commercial application would ultimately be dependent on research and development of a
simplified or automated process. As such, Biovest responded to an NCI CRADA announcement and proposed a collaboration toward this end. Biovest will leverage its cell culture, purification, and clinical instrument expertise to facilitate production
and commercialization of the idiotype tumor vaccine for B-cell lymphoma. Under the CRADA, a process and accompanying automated technology will be designed to produce and purify idiotype from each patient-specific cell line, both rapidly and cost
effectively in a cGMP environment. Biovest recognizes that this patient-specific approach is dependent on technology designed to address these needs. Unlike conventional biologicals or drugs, which benefit from mass production or economy of scale,
this new technology will be designed with the aim of allowing thousands of patient-specific vaccines to be manufactured efficiently each year. 
  
 Work Under this CRADA: The Phase 3 Clinical Trial. 
  
 To definitively answer the question of clinical efficacy, the NCI opened a multi-institutional, controlled, randomized Phase 3 clinical trial in January 2000 under the
auspices of the NCI Vaccine Working Group and with support from the Office of the Director. Given the fact that no cancer vaccine has been licensed for use in the United States, designing this trial as a scientifically rigorous test of the cancer
vaccine hypothesis, with scientific proof of principle as the primary objective, was felt to be paramount. Therefore, no changes in the key variables were (or will be) considered. Specifically, the design of the study remains identical to that of
the Phase 2 study. Specifically, only patients with previously untreated lymphoma of follicular types are eligible, all patients receive uniform PACE chemotherapy, and vaccination is therefore administered to a homogeneous group of patients in first
complete remission. Importantly, the vaccine formulation is also identical to that used in the Phase 2 trial, using the same hybridoma fusion technology to generate the vaccine, and using the same dose, schedule, and route of 

  

					
	 	 	A-6	 	CONFIDENTIAL

 
vaccine administration. A multi-center consortium of clinical sites has been assembled, including Northwestern University, University of Pennsylvania, Duke
University, Moffitt Cancer Center, and the NIH Clinical Center with additional sites under consideration. As of March 2001, approximately 50 patients have been enrolled on this study, which is currently being sponsored under NCI Investigational New
Drug Application (IND) 5427. 
  
 The trial is anticipated to enroll a total of 563
patients, approximately 2/3 of whom are expected to achieve a clinical complete remission from PACE chemotherapy. Patients achieving a complete remission are randomized to begin treatment with either a specific vaccine consisting of Id-KLH + GM-CSF,
or non-specific vaccine consisting of KLH + GM-CSF, in a 2:1 ratio (in favor of specific vaccine) starting six months after completion of chemotherapy. 
  
 This trial anticipates accrual over five years, and because of the long natural history of follicular lymphoma, an additional three years of follow-up time is projected
to observe at least a 20% improvement in disease-free survival (study endpoint) for the experimental group. 
  
 The achievement of scientific proof of concept remains the primary objective of this Phase 3 trial. The addition of a CRADA partner will allow the data from this trial to be put together in support of a BLA with the
FDA, which is necessary to help bring this vaccine to market. Furthermore, the CRADA partner’s contribution of intellectual property will allow for development of an automated system for the practical production of a vaccine to be brought to
market and fulfill a currently unmet public health need. Finally, the addition of a corporate partner may make it possible to accelerate patient accrual in order to complete the trial and provide data necessary to support a BLA with the FDA in a
shorter period of time. 
  
 Production of Id Vaccines. 

 
 Since Id is a clonal marker unique to each lymphoma, vaccines must be produced on an
individualized basis for each patient. The strategy used to isolate immunogloblin from the surfaces of human B-cell lymphomas consists of performing a hybridization between the lymphoma cell and a modified, mouse/human heteromyeloma cell that grows
in vitro and that has the cellular machinery to synthesize and secrete large quantities of immunoglobulin. Such myeloma fusion partners have been engineered not to secrete any immunoglobulin of their own; therefore, the immunoglobulin that is
secreted following fusion is derived purely from the human tumor. 
  
 The
production of Id protein begins with the isolation of malignant cells from tumor biopsy specimens, most commonly involved lymph nodes, although tumor cells isolated from peripheral blood, bone marrow or spleen can be used. The minimal starting
material consists of about 75 million tumor cells. These cells are then fused with a hypoxanthine-aminopterin-thymidine (HAT) - sensitive fusion partner, and hybridomas selected in HAT medium that secrete immuoglobulin with the type of heavy and
light chains corresponding to the known immunophenotype of the tumor specimen are identified. This is vaccine production process step 1. 
  
 Polymerase chain reaction (PCR) amplification of the immunoglobulin variable region genes from both the hybridoma and the primary tumor specimen are performed, and the
sequences are compared to establish the identify of the secreted immunoglobulin. This is vaccine production step 2. 
  
 Heterohybridomas identified in this way are expanded. This is vaccine production process step 3. 
  

					
	 	 	A-7	 	CONFIDENTIAL

 Id protein is the purified from collected culture supernatants by affinity chromatography depending on the isotype of the
lymphoma immunoglobulin. Each idiotype protein is then conjugated to KLH. These two processes are collectively referred to as vaccine production process step 4. 
  

This Id-conjugate is then used to immunize the patient from whose tumor it was originally isolated. 
  
 Vaccine production process Steps 1-2 are currently performed in Dr. Kwak’s laboratory at NCI-Frederick. Vaccine production process Step
3 is presently being conducted at Biovest under the Letter of Intent to this CRADA between Biovest and NCI executed January 9, 2001, and Step 4 is being performed under contract with Charles River Discovery & Development Services (CRDDC),
Rockville, MD through Science Applications International Corporation (SAIC), a contractor in the Government-Owned, Contractor Operated (GOCO) facility at NCI-Frederick . While currently performed in Dr. Kwak’s laboratory at NCI, the technology
for heterohybridoma fusion and selection and PCR sequencing will be transferred and optimized for GMP production at Biovest International. As noted above, the ultimate goal of this CRADA is to fully develop the technology allowing optimized Id
vaccine production under GMP conditions that would be necessary for FDA approval for human clinical use. As part of that goal, NCI and Biovest will investigate the automation of this stepwise production of Id vaccines using Biovest’s
proprietary instrument. 
  
 Under optimal conditions, approximately three months
are required for production of the final product. This time period does not constitute a limitation, as the vaccine administration occurs following six to eight months of cytoreduction with conventional chemotherapy and an additional six month rest
period. 
  
 Overall, the CRADA is an extension and combination of existing NCI and
Biovest systems and procedures for cell culture, purification and clinical instrument development. NCI and Biovest staff will undertake the cell fusion, gene sequencing, and purification/conjugation procedures. Combined with Biovest’s existing
intellectual property and instrument manufacturing experience, these procedures will be incorporated into a single instrument that can be applied to production and purification of personalized cancer vaccines in a clinical setting. It is envisioned
that several principle steps required to create this vaccine can be incorporated into an affordable, user-friendly technology, designed specifically for commercial production of this vaccine. 
  
 Ultimately, successful commercialization will depend on the capability to service large
numbers of patients economically. The autologous nature of this therapy places significant emphasis on creating an automated, yet individualized, manufacturing process for each patient. This “personalized” approach precludes the
efficiencies or economies of scale typically observed in commercial antibody production. It is estimated that a minimum of 15,000 patients (US only) per annum will seek vaccination. To realize that number (200 to 300 per week), an efficient and
affordable patient-specific Current Good Manufacturing Process (cGMP) is required. As such, an automated process for antibody production and purification becomes a key to the success of this approach. 
  
 Biovest is committed to expanding its technological capabilities in parallel with the first
two years of the Phase 3 clinical trial. Based on past experience, this is a reasonable timeline and will allow for equivalency studies, initial validation testing, and instrument manufacture suitable for FDA approval. Biovest laboratories also
contain cGMP space, as well as build-out capacity, if required, that can be dedicated to commercialization efforts. Beyond that space, an additional 12,000 square feet of FDA validated cGMP space is available for production and purification as the
Phase 3 clinical trial expands. Biovest has utilized hollow fiber technology for over 3 years and successfully operated isolation suites that parallel the needs for personal vaccine production. 
  

					
	 	 	A-8	 	CONFIDENTIAL

 Concurrent with cGMP process development, one objective is to demonstrate technology transfer (laboratory techniques)
from NCI to the oncology laboratory at NYU Medical Center. Biovest has recently acquired the support of NYU as both a consortium site and location for further expansion of the cell process procedures. Biovest personnel, trained at NCI, will move to
this facility and be utilized to train additional staff as needed. However, NYU is not a party to this CRADA. Biovest employees will be used for all activities in the NYU laboratory to conduct cell processing. 
  
 Upon initiation of the CRADA, Biovest will continue to manufacture the automated technology
and hollow fiber bioreactors. At present. Biovest has ample capacity to provide a suitable quantity of the bioreactors for an accelerated Phase 3 trial. Biovest has hired additional engineers, technicians and regulatory/quality specialists for
instrument and process development. 
  
 The goal is to transfer to Biovest working
at NYU the B-cell isolation techniques and the unique cell fusion, molecular sequencing and conjugation expertise developed at NCI. Biovest and NCI will work together to train skilled cellular immunologists and protein biochemists working for
Biovest at Biovest, or working at NYU under contract with Biovest. Since the ability to transfer this expertise to an additional laboratory is critical for commercialization of the vaccine, these personnel will be dedicated to the task of achieving
the requisite proficiency levels to meet the NCI requirements for such technology transfer. The ultimate objective is to establish material duplication of these procedures in other laboratories. Based on 15.000 vaccinations per year (U.S.), the
ability to set up at least one cGMP production facility for cell fusion, screening and molecular sequencing is essential. This will be done in parallel with the ongoing Phase 3 clinical trial to expedite the commercialization process. 
  
 It is important to emphasize that the transfer of NCI technology to Biovest’s
established laboratory at NYU will provide a format for successful transfer to a commercial production facility. 
  
 Enhancing Patient Accrual. 
  
 Additionally, Biovest intends to enhance patient accrual for the Phase 3 clinical trial by providing access to patients through the New York University (NYU) hospitals.
NCI and Biovest intend to further participate in patient accrual and shorten the time required to complete this study. 
  
 Further, Biovest will enhance national physician and patient awareness of this clinical trial by assuming responsibility for the marketing strategy. To do this, Biovest
is prepared to take several actions designed to increase patient accrual for the Phase 3 clinical trial. Biovest’s marketing firm has represented that these actions will include both direct and indirect promotional and marketing efforts.
Biovest’s promotional and marketing efforts related to and during the term of this CRADA will be reviewed and approved by NCI. It is anticipated that this promotional campaign will greatly accelerate patient accrual for this clinical trial.

  
 As set forth in the preceding sections, Biovest is equipped scientifically and
financially to collaborate with NCI to successfully perform all aspects of bringing this idiotype tumor vaccine through the final clinical trial and into commercial production. Because of their expertise in the field of hollow fiber perfusion
technology, they possess the necessary team of experienced engineers and scientific personnel to develop the cGMP process crucial to therapeutic application of this vaccine. It is anticipated that this vaccine production process will be complete and
a broadly accessible therapy prior to conclusion of this 

  

					
	 	 	A-9	 	CONFIDENTIAL

 
Phase 3 study. Associated with instrumentation, and following FDA approval, the hollow fiber bioreactor manufacturing will be implemented to fulfill the
large number of anticipated vaccines. The objective is to incorporate automated technology with cGMP production processes, such that this personalized approach to the treatment of lymphoma can be brought to market to answer an unmet public health
need. 
  
 WORK SCOPE OF PROPOSED CRADA

  
 The scope of this CRADA includes the development of the processes required
for large-scale GMP production of adequate numbers of GMP-produced and formulated idiotype vaccines to complete the clinical development of this treatment for follicular B-Cell lymphoma. This vaccine strategy involves the use of an immunological
adjuvant, GM-CSF, which is currently being supplied to NCI for this study under a Clinical Trial Agreement with Immunex. Such processes may include, but are not limited to refinement of GMP process and automation of the vaccine production.

  

					
	 	 	A-10	 	CONFIDENTIAL

 RESPECTIVE CONTRIBUTIONS OF THE PARTIES 
  

	A.	Joint Responsibilities 

  

	1.	Steering Committee- Once Biovest establishes its own IND, the Parties agree to establish a joint clinical development team whose responsibility will be the oversight of the ongoing
Phase 3 Clinical Trials performed under the Collaborators IND related to this CRADA. The Steering Committee will comprise the following NCI staff: the Principal Investigator, the Project Officer for Vaccine Production, the Protocol Coordinator, the
Protocol Chairman, and the following Collaborator staff: Principal Investigator, and appropriate Collaborator staff in the areas of clinical monitoring, pharmacy, statistics, manufacturing and publicity. Although the members of the Steering
Committee shall be considered as having been delegated to the Steering Committee, they shall continue to remain employed by their respective employers under their respective terms of employment. 

  

	2.	Both parties to the CRADA will provide independent statistical expertise and work closely together to ensure that the CRADA clinical trial moves forward expeditiously. Activities
conducted in support of this obligation include providing public notice and promotion of the clinical trial to foster patient accrual. 

  

	3.	Both parties to the CRADA shall collaborate in the collection and analysis of data from the clinical trial. 

  

	4.	Both parties to the CRADA will evaluate the study as it progresses to ensure that the appropriate questions are being addressed and to ensure that the study is modified as required
based on the developing data. The DCTD will utilize its existing procedures and mechanisms to follow the clinical study to ensure that the study meets the pertinent FDA regulations until Biovest receives an approved IND for this technology.

  

	5.	Both parties to the CRADA will meet with the FDA jointly to discuss protocol and requirements necessary for the study to support a Biologic License Application with the FDA

  

	6.	Both parties to the CRADA will work closely together to develop processes for commercial cGMP production of Id-KLH follicular B-cell lymphoma vaccine with GM-CSF as adjuvant.

  

	B.	NCI Responsibilities 

  
 The National Cancer Institute contribution to the collaborative research and clinical development of Id-KLH indolent follicular lymphoma vaccine includes the following: 
  

	1.	Dr. Larry Kwak will serve as the NCI Principal Investigator for this CRADA. As such, he will be the senior author on any scientific publications resulting from these clinical
trials, and will be the final arbiter for the inclusion of co-authors on publications. In the unforeseen event that Dr. Kwak should leave NCI before completion of this clinical trial, NCI will designate an alternative Principal Investigator for the
CRADA, but Dr. Kwak will retain the senior authorship position on publications resulting from the randomized, Phase III clinical trial protocol #00-C-0050 (P-92). NCI will be the final arbiter for amendments to Phase ffl clinical trial protocol
#00-C-0050 (P-92). 

  

					
	 	 	A-11	 	CONFIDENTIAL

	2.	Subject to the provisions of Articles 8.3 and 10.6 hereunder. the CCR will collaborate solely with Collaborator for development of Agent under NCI protocol #00-C-0050 (P-92).

  

	3.	As the sponsor of protocol #00-C-0050 (P-92), the NCI through its Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP), has submitted a
protocol to the FDA under an Investigational New Drug Application (IND) for Agent and the CCR has provided an IRB-approved protocol, which designates the CCR as the lead clinical institution. The DCTD will maintain the IND (#5427), including all
supporting preclinical toxicology data, protocol #OO-C-0050 (P-92), investigator qualifications, and other supporting information relative to Agent in DCTD’s possession and control and will permit Collaborator to review, cross-reference only
information related directly to this clinical trial in the END for conducting the clinical trial and in fulfilling all of the requirements necessary for obtaining FDA approval to market Agent. 

  

	4.	The CCR will be responsible for vaccine production steps 1, 2 and 4 in the production of Id-KLH indolent follicular lymphoma vaccine used in support of NCI Protocol #00-C-0050
(P-92) under this CRADA until Biovest has proven fully capable to assume these activities, approximately 12- 18 months after execution of this CRADA #01030. 

  

	5.	The CCR will work with Biovest in development of processes necessary for Collaborator to perform vaccine production steps 1- 4 in the production of Id-KLH indolent follicular
lymphoma vaccine in support of NCI Protocol #00-C-0050 (P-92). 

  

	6.	Using NCI immunologic assays, and molecular monitoring assays currently under development, the CCR will examine these surrogate endpoints in support of NCI protocol #00-C-0050
(P-92). 

  

	C.	Biovest Responsibilities 

  

	1.	Subsequent to the execution of NCI CRADA #01030, and prior to Biovest receipt or review of any clinical trial data generated under this CRADA, Biovest shall, with NCI’s
approval, work with all clinical sites to make IRB-approved modifications to the patient informed consent document to address tissue banking and commercial entity review of patient clinical data and to re-consent all patients enrolled in the
clinical trial. 

  

	2.	Collaborator will schedule a pre-IND conference with the FDA, and subsequently, prepare and submit an IND to the FDA with the object of obtaining regulatory approval of Id-KLH
follicular B-cell lymphoma vaccine with GM-CSF as adjuvant for follicular B-cell lymphoma patients who have attained a complete clinical response from chemotherapy. 

  

	3.	 Within one year of execution of CRADA #01030, it is anticipated that Collaborator will file and have an approved END for the Agent. Upon such approval, Collaborator
will provide assurance (letter) to DCTD that the IND was filed and that the FDA concurred with the transfer of NCI Protocol #00-C-0050 (P-92) to Biovest. Subject to the provisions of Articles 8.4, 8.10 and 13.1 hereunder, the Collaborator will then
be responsible for: adverse event monitoring and reporting, drug distribution, clinical data collection, and protocol amendments for NCI Protocol #00-C- 0050 (P-92). If Biovest fails to establish an approved IND within 18 months then, at NCI’s

  

					
	 	 	A-12	 	CONFIDENTIAL

	 	 
discretion, the CRADA may be terminated per Article 10. Timelines may be extended by NCI for delays not under the control of the Collaborator including but
not limited to delays within the FDA. NCI will seriously consider Collaborator’s request for an extension of this timeline for delays not under the control of the Collaborator. 

  

	4.	Upon execution of the CRADA, Collaborator will perform vaccine production step 3 and provide hybridoma supematants in the production of Id-KLH indolent follicular lymphoma vaccine
in support of NCI Protocol #00-C-0050 (P-92). 

  

	5.	Upon transfer of NCI Protocol #00-C-0050 (P-92) to Collaborator. Collabortor will be responsible for supply of Immunex GM-CSF for NCI Protocol #00-C-0050 (P-92).

  

	6.	Collaborator will perform vaccine production steps 1, 2 and 4 in the production of Id-KLH indolent follicular lymphoma vaccine in support of NCI Protocol #00-C-0050 (P-92) when
Collaborator has proven fully capable to assume these activities approximately 12-18 months after execution of CRADA #01030. 

  

	7.	Collaborator will conduct studies as necessary with the goal of optimizing and automating vaccine production and refining and validating production procedures as required by the
FDA. 

  

	8.	Subject to the provisions of Articles 8.4, 8.10 and 13.1 hereunder. Collaborator will develop an electronic archive for storage and retrieval of study-related data as required by
the FDA for submission of data in support of a BLA. 

  

	9.	Upon execution of the CRADA, Collaborator will provide funds for data monitoring activities directly to EMMES Corporation, the NCI’s current contract research organization for
data monitoring activities related to NCI Protocol #00-C-0050 (P-92), as set forth in CRADA Appendix B. 

  

	10.	Collaborator will provide long-term patient monitoring to determine overall survival outcomes. 

  

	11.	Collaborator will arrange, host and provide support for: monthly production/manufacturing meetings between Biovest and NCI staff for discussion of production-related issues and ;
meetings associated with the Protocol Steering Committee and the Oversight Committee and; quarterly site visits by appropriate NCI and Biovest staff to each clinical consortium site and; clinical investigators meetings as needed (anticipated every
6-12 months). 

  

	12.	For activities conducted pursuant to this CRADA in the United States of America, Collaborator, to the extent it engages in applicable conduct, agrees to comply with all appropriate
DHHS regulations relating to Human Subjects Use, all U.S. Department of Agriculture regulations, and all Public Health Service policies relating to the use and care of laboratory animals. For activities conducted pursuant to this CRADA outside of
the United States of America, Collaborator shall conduct such in accordance with Good Laboratory Practices (GLPs) and all applicable rules, regulations and statutes, both local and national, governing such activity in that country.

  

	13.	Collaborator agrees to provide the NCI a redacted version of this CRADA suggested for release under Freedom of Information Act (FOIA) requests. 

  

					
	 	 	A-13	 	CONFIDENTIAL

	14.	Biovest will seek, with NCI approval, to accelerate patient accrual to NCI Protocol #00-C-0050 (P-92) by: 

  
 (l) supporting protocol-related patient care and personnel costs at
extramural consortium sites and; 
  
 (2) by providing aggressive
promotional and marketing efforts subject to NCI approval. These efforts will be comprehensive, including, at a minimum, engaging a professional marketing firm, nationwide direct marketing to referring doctors, organizing and sponsoring seminars in
each of the geographic areas represented by current and future clinical consortium centers nationwide, and developing an interactive website. 
  
 References: 
  

	1.	Longo DL, Young RC, DeVita VT. What is so good about the “good prognosis” lymphoma? in Williams CG, Whithouse JMA (eds.): Recent Advances in Clinical Oncol Edinburgh,
Churchill- Livingstone, pp. 223-231, 1982. 

  

	2.	Portlock CS. “Good risk” non-Hodgkin’s lymphomas: Approaches to management. Sem Hematol, 1980, 20:25-34. 

  

	3.	Portlock CS, Rosenberg SA. No initial therapy for stage 3 and IV non-Hodgkin’s lymphomas of favorable histologic types. Ann Intern Med. 1979,90:10-13. 

 

	4.	Homing SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med, 1984,311:147-5. 

  

	5.	Stevenson GT, Stevenson FK. Antibody to molecularly defined antigen confined to a tumor cell surface. Nature. 1975, 254:714-6. 

  

	6.	Stevenson GT, Elliott EV, Stevenson FK. Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target. Fed Proc. 1977, 36:2268-71.

  

	7.	Sirisinha S, Eisen HN. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Natl Acad Sci USA. 1971. 68:3130-5. 

  

	8.	Lynch, R. G., R. J. Graff, S. Sirisinha, E. S. Simms, and H. N. Eisen. Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl.Acad. Sci. USA, 1972, 69:1540.

  

	9.	Jorgensen T, Gaudernack G, Hannestad K. Immunization with the light Chain and the VL domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC- 315.
Scand J Immunol. 1980, 11:29-35. 

  

	10.	Daley MJ, Gebel HM, Lynch RG. Idiotype-specific transplantation resistance to MOPC-315: Abrogation by post-immunization thymectomy. J Immunol. 1978, 120:1620-4.

  

					
	 	 	A-14	 	CONFIDENTIAL

	11.	Bridges SH. Participation of the humoral immune system in the myeloma-specific transplantation resistance. J Immunol. 1978, 121:479-83. 

  

	12.	Freedman PM, Autry JR, Tokuda S, Williams RC, Jr. Tumor immunity Induced by preimmunization with BALB/c mouse myeloma protein. J Natl Cancer Inst 1976, 56:735-740.

  

	13.	Sugai S, Palmer DW, Talal N, Witz IP. Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB/NZWF1 mice. J Exp Med. 1974,
140:1547-58. 

  

	14.	Stevenson FK, Gordon J. Immunization with idiotypic immunoglobulin Protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by
modulation. J Immunol. 1983, 130:970-973. 

  

	15.	George AJT, Tutt AL, Stevenson FK. Anti-idiotypic mechanisms involved in the suppression of a mouse B cell lymphoma, BCL. J Immunol. 1987, 138:628-634.

  

	16.	Kaminski MS, Kitamura K, Maloney DG, Levy R. Idiotype vaccination Against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol. 1987,
138:1289-1296. 

  

	17.	Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B cell lymphoma against the surface immunoglobulin idiotype expressed
by their tumors. N Engl J Med, 1992, 327:1209-1215. 

  

	18.	Kwak LW, Young HA, Pennington RW, Weeks SD, Vaccination with syngeneic, lymphoma- derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor
primes mice for a protective T-cell response. Proc Natl Acad Sci USA 1996 Oct 1; 93(20): 10972-7. 

  

	19.	Bendandi MB, Gocke C, Kobrin C, Benko F, Stemas L, Pennington R, Watson T, Reynolds C, Gause B, Duffey P, Jaffe E, Creekmore S, Longo D, and Kwak LW. Complete molecular remissions
induced by patient-specific vaccination plus GM-CSF against lymphoma. Nat Med. 5:1171-1177, 1999. 

  

					
	 	 	A-15	 	CONFIDENTIAL

 DESCRIPTION OF OTHER NCI-BIOVEST INTERNATIONAL, INC. AGREEMENTS AND INTELLECTUAL PROPERTY OF THE
PARTIES 
  

			
	 CRADAs:
	  	None
		
	 MTAs:
	  	None
		
	 CTAs:
	  	None

  

	CDAs: 	2-02244-01; “Discussions for the entering into of a Cooperative Research & Development Agreement (‘CRADA’) for the development and production of idiotype vaccines
against B-cell lymphoma “; Executed November 20, 2000. 

  
 PATENTS/PATENT APPLICATIONS: 
  
 Biovest International

  
 Patent 
  
 US Patent 4,804,628, Hollow Fiber Cell Culture Device and Method of
Operation. 
  
 US Patent 5,079,168. Cell Culture Apparatus.

  
 US Patent 5,416,022. Cell Culture Apparatus. 
  
 US Patent 5,330,915. Pressure Control System for a Bioreactor 
  
 US Patent 4,629,686. Apparatus for Delivering a Controlled Dosage of a
Chemical Substance. 
  
 US Patent 4,618,586. Apparatus for
Delivering a Controlled Dosage of a Chemical Substance Having an Improved Culture Chamber. 
  
 US Patent 4,650,766. Culturing Apparatus 
  
 US Patent 297,620. Multi-Port Fitting for a Flask 
  
 US Patent 5,202,254. Process for Improving Mass Transfer in a Membrane Bioreactor Providing a More Homogeneous Culture Environment. 
  
 US Patent 4,722,902. Apparatus and Method for Culturing Cells, Removing Waste, and Concentrating Product. 
  
 US Patent 4,973,558. Method of Culturing Cells Using Highly Gas Saturated
Media 
  
 US Patent 6,001,585 Micro Hollow Fiber Bioreactor.

  
 US Patent 4,889,812. Bioreactor Apparatus 
  
 US Patent 4,894,342 Bioreactor System 
  
 US Patent 5,656,421 Multi-Bioreactor Hollow Fiber Cell Propagation System
and Method 
  
 US Patent 5,998,184 Basket-Type Bioreactor

  

					
	 	 	A-16	 	CONFIDENTIAL

 Non-Patented Intellectual Property 
  
 Biovest has been a leader in developing the hollow fiber bioreactor market. In the process,
Biovest has developed a number of preferred and alternate methods, vendors, and customers. This knowledge base is proprietary and is not the subject of this CRADA. 
  
 Abstract of the Research Plan of the CRADA 
  

The National Cancer Institute (NCI) has initiated an FDA-approved, multi-institutional Phase 3 clinical trial of protein-based immunoglobulin idiotype vaccines for the
treatment of low-grade follicular B-cell lymphoma. B-cell tumors are composed of clonally-expanded cells synthesizing a single antibody molecule containing unique variable regions known as idiotypic determinants. The idiotypic determinants of B-cell
derived tumors comprise tumor-specific antigens that can serve as a target for immunotherapy. Based on success of earlier clinical trials (Nature Medicine 5: 1171-1177, Oct. 1999), NCI has decided to partner with Biovest International, Inc.
(Biovest) in furtherance of the clinical study and scale-up work necessary for further vaccine production and eventual FDA product commercialization. A specific goal of this CRADA will be development of the processes required for automated
large-scale GMP production of adequate numbers of GMP produced and formulated idiotype vaccines as needed to complete the clinical development of this agent for the treatment of follicular B-cell lymphoma. 
  

					
	 	 	A-17	 	CONFIDENTIAL

 APPENDIX B 
  
 FINANCIAL AND STAFFING CONTRIBUTIONS OF THE PARTIES 
  
 National Cancer Institute 
  
 Personnel 
  
 The NCI estimates that 1.45 professional person years/year of effort will be dedicated to its participation in the clinical study, Steering Committee Meetings, updates to
its END, compiling data, data management and monitoring in support of the clinical trial, vaccine handling and distribution to consortium sites, pathology and radiology review, and vaccine production. Such estimate of PHS staff includes its
Principal Investigator (0.25 person years/year) and sufficient staffing to execute and fulfill the obligations of the CRADA, including a Protocol Chairman (0.5 person years/year), a Project Officer for Vaccine Production (0.5 person years/year), a
Central Pathologist (0.1 person years/year) and a Central Radiologist (0.1 person years/year) 
  
 NCI will provide no funding to the Collaborator for collaborative research and development pursuant to this CRADA in as much as financial contributions by the U.S. government to non-federal parties under a CRADA are
not authorized under the Federal Technology Transfer Act (15 U.S.C. §3710(d)(l)). 
  
 Biovest International 
  
 Personnel: 
  
 Biovest intends to commit 50 to 60 person years per year of effort to permit the timely execution of the study implemented under this CRADA. More specifically, this
staffing shall include Biovest full-time employees, consultants to the company, external contract agencies and contract research organizations and personnel. 
  
 Funding: 
  
 NCI-CCR Costs 
  
 Collaborator shall
provide $530.000.00 dollars quarterly for reasonable and necessary expenses incurred by NCI in carrying out its responsibilities associated with conduct of the clinical trial under this CRADA and are to be deposited to an NCI CAN account established
for the administration of this CRADA. No full-time tenured employees will be supported under this CRADA by Biovest International, Inc. However, Collaborator funds provided under this CRADA will be used to support a Protocol Coordinator, a Research
Nurse, a Data Manager and a Materials Coordinator. These expenses include, but are not limited to, costs associated with cGMP lymph node biopsy processing, tumor cell fusions, PCR sequencing of tumor biopsies and fusions, and purified Id-KLH
and KLH-KLH vaccine production, molecular and immunologic monitoring, publication of clinical trial, supplementation of support services contracts and shipment of samples, vaccine production, associated administration support and
professional meetings support related to the CRADA, transportation and lodging costs to support the participation of NCI staff at semi-annual Principal Investigator meetings and for quarterly site visits to 

  

					
	 	 	B-1	 	CONFIDENTIAL

 
consortium centers and monthly vaccine production meetings. The First payment will be due within thirty days of the execution of the CRADA with future
payments due on the quarterly anniversary date of the execution of the CRADA. Travel costs are limited by the Federal Travel Rules and Regulations for all government staff whether paid for by government funds or private Collaborators. Collaborator
may provide direct support, under the 348 travel mechanism, for the travel and associated costs for attendance of NCI staff at selected scientific or development meetings. 
  
 A check in the amount of $530.000.00 will be provided to the NCI by Biovest within thirty (30) days of the execution of the CRADA. Checks
should be made payable to the “National Cancer Institute”, should reference the CRADA #01030 and be sent to: CRADA Funds Coordinator, Technology Transfer Branch, EPS-450, 6120 Executive Blvd., Rockville, MD 20852. 
  
 NCI/CTEP Funding Due 
  
 Biovest will be responsible for the following payments to CTEP for the costs associated with
NCI’s sponsorship of the clinical study under this CRADA. These payments are to provide support to CTEP for the costs associated with continuing to conduct the clinical trial under this CRADA including drug and data management and to support
activities to facilitate the transfer of the protocol as well as in support of protocol amendments, filings and interactions with the FDA in order to ensure patient safety in the transfer of the study. 
  

			
	Year One:	  	Within thirty (30) days of the execution of NCI CRADA #01030, Biovest will remit to CTEP, NCI One Hundred Thousand dollars ($100,000.00) for the costs associated with NCI’s sponsorship
of the study and development of the pharmaceutical distribution system for the randomized, blinded study.
		
	Year Two:	  	Within one year of the execution of NCI CRADA #01030, Biovest is expected to file and have an approved END on file with the FDA for the Agent. If Biovest fails to receive an approved END for
the Agent within one year of the date this CRADA is executed, Biovest shall remit to CTEP an additional Fifty Thousand dollars ($50,000.00) to a maximum of One Hundred Thousand Dollars ($100,000.00); the exact amount to be determined by CTEP based
on the number of patients enrolled on the study at that time and the number of sites participating. It is expected that additional sites will be added over those present at the execution of this CRADA during Year One which will increase patient
accrual to the trial. If that occurs, the payment due will be One Hundred Thousand Dollars.

  
 If Biovest fails to receive an
approved END within 18 months from the date this CRADA is executed, the CRADA may, at NCI’s sole discretion, be terminated by NCI per Article 10. NCI will seriously consider Collaborator’s request for an extension of this timeline for
delays not under the control of the Collaborator. If NCI does not terminate this CRADA and continues to hold the END, Biovest will continue to provide funds to CTEP, NCI for continued support of the trial for this Agent. The annual payment due will
be no less than one hundred thousand dollars for the duration of NCI’s sponsorship of the study. 
  
 Checks should be made payable to the “National Cancer Institute”, should reference the CRADA #01030 (CTEP CAN) and be sent to: CRADA Funds Coordinator, Technology Transfer Branch, EPS-450, 6120 Executive
Blvd., Rockville, MD 20852 for deposit into a separate CTEP Cost Accounting Number 

  

					
	 	 	B-2	 	CONFIDENTIAL

 
(CAN). A copy of the check and cover letter should be faxed to Dr. Sherry Ansher at 301-402-1584 prior to mailing. 
  
 Any adjustments will be made by amendment pursuant to Article 13.6 hereunder. Adjustments to
the above-noted costs, with the exception of the costs related to CTEP support, will be made on a yearly basis as mutually agreed upon by both parties, taking into account the level of control Biovest assumes for these responsibilities, the rate of
patient accrual, and the overhead costs associated with, but not limited to, increase in cost of living. 
  
 Data Monitoring Costs by The EMMES Corporation (EMMES) 
  
 Collaborator shall provide the funds directly to, EMMES, required to support data monitoring activities of the Study conducted by EMMES.

  
 Direct Patient costs 
  
 Collaborator agrees to provide directly to the clinical site(s) up to $5,000 per patient
that is assigned an NIH Clinical Center Number, for reasonable and necessary expenses incurred by Extramural Consortium Site Investigators in carrying out its responsibilities associated with conduct of the clinical trial under this CRADA. These
expenses include but are not limited to costs associated with data collection and lymph node biopsy processing at selected extramural consortium sites. 
  

					
	 	 	B-3	 	CONFIDENTIAL

  
 APPENDIX C 

 
 EXCEPTIONS OR MODIFICATIONS TO THIS CRADA 
  
 Modify Article 1 to read as follows:  
  
 Article 1. Introduction 
  
 This Cooperative Research and Development Agreement (CRADA) between PHS and the Collaborator will be effective when signed by all Parties.
The research and development activities which will be undertaken by each of the Parties in the course of this CRADA are detailed in the Research Plan (RP) which is attached as Appendix A. The funding and staffing commitments of the Parties are set
forth in Appendix B. Any exceptions or changes to the CRADA are set forth in Appendix C. A copy of the Letter of Intent and Extension to the Letter of Intent are included as Appendix D for informational purposes. This Cooperative Research and
Development Agreement (CRADA) between PHS and the Collaborator will be fully executed when signed by all Parties and effective retroactively with regard to intellectual property and confidentiality to January 09. 2001. which is the date of the
execution of the Letter of Intent (LOI). This CRADA is made under the authority of the Federal Technology Transfer Act, 15 U.S.C. 3710a and is governed by its terms. 
  
 Modify Article 2.11 as follows: 
  

	2.11	“Subject Data” means all recorded information first produced in the performance of this CRADA by the parties. “Subject Data” shall specifically exclude
“Identifiable Private Information.” 

  
 Add the following
new sections to the Article 2. Definitions: 
  

	2.12	“Adverse Drug Experience” means an adverse clinical experience as defined under 21 C.F.R. 312.32. 

  

	2.13	“Agent” means Id-KLH follicular B-cell lymphoma vaccine administered in combination with GM-CSF adjuvant. 

  

	2.14	“Annual Report” means the brief report of the progress of an IND associated investigation which the IND sponsor is required to submit to the FDA within 60 days of
the anniversary date that the IND went into effect (pursuant to 21 C.F.R. 312.33). 

  

	2.15	“Clinical Data and Results” means all information, data and results developed or obtained in connection with clinical trials conducted within the scope of the CRADA
Research Plan whether by intramural research scientists or extramural grantee or contract investigators. 

  

					
	 	 	C-1	 	CONFIDENTIAL

	2.16	“Clinical Data and Results and Raw Data in NIH’s Possession and Control” means all information collected from NIH intramural preclinical or clinical
studies performed pursuant to the Research Plan, all data obtained by NIH under contracts with extramural contract investigators for completion of studies within the scope of the CRADA Research Plan, and all information and data in the NCI-sponsored
IND for Agent. 

  

	2.17	“Contract” means a funding agreement that is a research and development contract that provides that the contractor perform for the benefit of the Government, with
an expectation of completion of the stated research goals and the delivery of a report, data, materials or other product. Generally, Contracts are administered under the Federal Acquisition Regulations (FAR) codified at Title 48 C.F.R., Chapter 1 or
the Health Services Acquisition Regulations (HSAR) codified at Title 48 C.F.R., Chapter 3. 

  

	2.18	“Cooperative Agreement” means a Funding Agreement that is a species of a grant, whereby the funding Federal agency intends to be substantially involved in carrying
out the research program. Cooperative Agreements may be used where the Federal agency intends for its scientists to directly collaborate with the researchers of the funded institution on a joint research project. The Federal agency may then pay for
the research of both its employees and those of the funded institution (see 45 C.F.R. Part 74). 

  

	2.19	“CTA” means Clinical Trial Agreement. 

  

	2.20	“CTEP” means the Cancer Therapy Evaluation Program, DCTD, NCI, the program within NCI which plans, assesses and coordinates all aspects of clinical trials including
extramural clinical research programs, internal resources, treatment methods and effectiveness, and compilation and exchange of data. 

  

	2.21	“DCTD” means Division of Cancer Treatment and Diagnosis, NCI. 

  

	2.22	“FDA” means US Food and Drug Administration. 

  

	2.23	“Funding Agreement” means a Contract, Grant or Cooperative Agreement entered into between a Federal agency and another party for the performance of experimental,
developmental, or research work funded in whole or in part by the Federal Government. 

  

	2.24	“Grant” means a funding agreement that is an award of financial assistance which may be provided for support of basic research in a specific field of interest to
the funding Federal agency. 

  

	2.25	“IND” means an Investigational New Drug Application submitted to the FDA to receive approval to conduct experimental clinical trials. 

  

	2.26	“Multi-Party Data” means clinical data from clinical studies sponsored by NCI pursuant to CTAs or CRADAs, where such data are collected under protocol involving
combinations of investigational agents from more than one CTA or CRADA collaborator, 

  

	2.27	“NCI” means the National Cancer Institute, NIH, PHS, DHHS. 

  

					
	 	 	C-2	 	CONFIDENTIAL

	2.28	“Protocol Review Committee” (or “PRC”) means the CTEP/DCTD committee that reviews and approves studies involving NCI investigational agents and/or
activities supported by NCI. 

  

	2.29	“Raw Data” means the primary quantitative and empirical data first collected by the intramural and extramural investigators from experiments and clinical trials
conducted within the scope of the Research Plan of this CRADA . 

  

	2.30	“Steering Committee” means a joint clinical development team (hereinafter referred to as the “Steering Committee”) the Parties agree to establish once
Biovest establishes its own END whose responsibility will be the oversight of the ongoing Phase 3 Clinical Trials performed under the Collaborators IND related to this CRADA The Steering Committee will comprise the following NCI staff: the Principal
Investigator, the Project Officer for Vaccine Production, the Protocol Coordinator, the Protocol Chairman, and the following Collaborator staff: Principal Investigator. and appropriate Collaborator staff in the areas of clinical monitoring,
pharmacy, statistics, manufacturing and publicity. Although the members of the Steering Committee shall be considered as having been delegated to the Steering Committee, they shall continue to remain employed by their respective employers under
their respective terms of employment. 

  

	2.31	“Oversight Committee” means the joint NCI Collaborator research and development team to be established upon execution of this CRADA and whose composition shall
include, but not be limited to: The NCI PI. the Collaborator P.I, the Project Officer for Vaccine Production, and the Vice-President of the Collaborator. The responsibilities of the Oversight Committee will include oversight of the fiscal
expenditures under the CRADA and review and approval of any possible third party involvement in any aspect of the CRADA Research Plan. Others may be added to this committee as mutually agreed upon by both parties. Although the members of the
Oversight Committee shall be considered as having been delegated to the Oversight Committee, they shall continue to remain employed by their respective employers under their respective terms of employment. 

  

	2.32	“Identifiable Private Information” means patient-identifying data from medical records or attached to patient specimens, to be obtained prospectively or from stored
medical records or specimens, that can be linked to individual human subjects, either directly or indirectly through codes. 

  
 Add the following new sections to the Article 3. Cooperative Research: 
  

	3.3	Review of Work. Periodic conferences shall be held by the Steering Committee to review work progress. It is understood that the nature of this cooperative research precludes
a guarantee of its completion within the specified period of performance or limits of allocated financial or staffing support. Accordingly, research under this CRADA is to be performed on a best efforts basis. 

  

	3.4	 Clinical Protocol. Clinical protocol proposals for each study within the scope of the CRADA Research Plan will be solicited from selected intramural and
extramural clinical investigators. Each clinical protocol should describe in detail the research to be conducted and
must DC submitted to the PRC for approval prior to implementation. Each clinical protocol received by NCI will be forwarded to Collaborator for review and comment approximately two weeks before 

  

					
	 	 	C-3	 	CONFIDENTIAL

	 	 
it is reviewed by the PRC. Comments from Collaborator received by CTEP before the PRC meeting will be discussed by the PRC, will be given due consideration,
and will be incorporated into the protocol, absent good cause. Comments from either Collaborator or the CTEP staff that are agreed upon in the PRC meeting will DC formatted as a consensus review, which is returned to the investigator for necessary
and/or suggested changes before the protocol can DC given Final approval and submitted to the FDA. A copy of the final approved protocol will be forwarded to Collaborator at the same time as it is submitted to the FDA. NCI protocol #00-C-0050
(P-92), entitled ‘Phase 3 Randomized Study of Autologous Lvmphoma Derived Idiotype Specific Vaccination Plus Sargramostim (GM-CSF) in Patients with Indolent Follicular Lvmphoma in First Complete Remission’ will be transferred to
Collaborator upon FDA approval of Collaborator’s IND application. 

  

	3.6	Investigational New Drug Application. The Parties expect that either NCI or Collaborator will submit an END which may will cross-reference an IND #5427 or Drug
Master File held by the NCI, under which the clinical study related to this CRADA is currently ongoing, other. All
information in IND’s will DC fully sri tired between NCI and Collaborator, except as TOT lows: If NCI files an IND for Agent that is the subject of this CRADA, Collaborator may, at its option supply information in support of the IND in the form
of a Drug Master File directly to the FDA so long as Collaborator grants NIII a right to cross-reference such information in its IND filing. In the event that Collaborator supplies CONFIDENTIAL information directly to NCI in support of an NCI IND,
such information will be protected in accordance with the corresponding Confidentiality provisions of Article 8 of this Agreement. 

  

	3.7	Biologics License Application. The parties expect that Collaborator will submit a Biologies License Application to the FDA within six (6) months from the NIH Data Safety and
Monitoring Board’s final analysis of results of the clinical trial or be considered to have abandoned its commercialization efforts. Collaborator shall have the right to file an application for “fast-track” licensing of Agent at any
time during the term of this CRADA once Collaborator has an approved END on file with the FDA. 

  

	3.8	Drug Information and Supply. Collaborator agrees to provide NCI without charge formulated and acceptably-labeled clinical-grade Agent in sufficient quantity to complete the
preclinical studies and clinical trial protocol sponsored by NCI within the scope of the CRADA Research Plan. It is understood that NCI shall take responsibility for and reasonable steps to maintain appropriate records and assure appropriate supply,
handling, storage, distribution and usage of these materials in accordance with the terms of this Agreement, the protocol and any applicable laws and regulations relating thereto. 

  
 Upon FDA approval of Collaborator’s IND and transfer of NCI protocol
#00-C-0050 (P-92) to Collaborator. Collaborator agrees to take responsibility and shall arrange directly with Immunex for provision and distribution of adjuvant GM-CSF necessary to complete the clinical trial performed under this CRADA 

 
 Further more, Collaborator agrees to provide without charge Agent 01
unformulated analytical grade Agent or metabolites, if available to NCI to supply external investigators for the development of mutually agreed upon analytical assays or ancilliary correlative studies conducted 

  

					
	 	 	C-4	 	CONFIDENTIAL

 
in conjuction with NCI sponsored protocols. Collaborator will provide Certificates of Analysis to NCI for each lot of finished product provided. Collaborator
further agrees to provide draft Agent labels to the Pharmaceutical Management Branch (PMB) for review and agrees to reasonable labeling revisions to comply with DCTD label guidelines. Collaborator agrees to supply sufficient inventory to ensure
adequate and timely supply of Agent for mutually agreed upon protocol(s). Changes in the composition or manufacture of the Agent for the studies performed under this CRADA will be mutually agreed upon by both parties. 
  
 The contact person for NCI will be Mr. Alfred Fallavollita, Chief,
Pharmaceutical Management Branch (Telephone Number 301-496-5725) and the Collaborator contact will be Dr. Chris Kyriakides, Chief Executive Officer, Biovest (Telephone Number 201-816-8900). 
  

	3.9	Protection of Human Subjects and Appropriate Care of Laboratory Animals. All human clinical trials performed under this CRADA shall conform to the appropriate Federal law,
including, but not limited to all applicable FDA regulations and DHHS regulations relating to the protection of human subjects (see 45 C.F.R. Part 46, 21 C.F.R. Parts 50 and 56). NCI and Collaborator also agree to comply with all applicable Federal
statutes and Public Health Service policies relating to the use and care of laboratory animals (see 7 U.S.C. 2131 et seq.) Additional information is available from the Office for Human Research Protections, Telephone: 301-496-7163. In accordance
with the HHS Office for Human Research Protections guidelines, private patient identifiable information shall only be used by Collaborator for licensing applications to the FDA, if required. All other uses of information under this Agreement shall
assure that no private patient identifiable information is disclosed. 

  
 Amend Article 4.1 “Interim Reports” to read as follows: 
  

	4.1	Interim Reports. The Parties shall exchange formal written interim progress reports on a schedule agreed to by the PIs, but at least within twelve (12) six (6) months after
this CRADA becomes effective and at least within every twelve (12) six (6) months thereafter. Such reports shall set forth the technical progress made, identifying such problems as may have been encountered and establishing goals and objectives
requiring further effort, any modifications to the Research Plan pursuant to Article 3.2, and identify Subject Inventions pursuant to Article 6.1. Oversight Committee reports or copies of CRADA Annual Reports updating the progress of the CRADA
research shall satisfy the reporting requirements under this Article 4.1. In addition, copies of the Annual Reports and other pertinent IND data related to NCI protocol # 00-C-0050 (P-92) (including, but not limited to. clinical brochure data, and
formulation and preclinical data^ including toxicology findings) shall be exchanged by the Parties as they
become available. 

  
 Add a new Article 43 as follows:

  

	4.3	 Adverse Drug Experience Reporting. Until NCI Protocol #00-C-0050 (P-92) is transferred to Collaborator. DCTD NCI shall report all serious or unexpected
adverse events to FDA in accordance with the reporting obligations of 21 CFR 312.32 and will, concurrently, forward all such reports to Collaborator . All other adverse event reports received by DCTD. NCI shall be reported to the FDA consistent with
21 CFR 312.32 and 312.33. In addition, copies of the Annual Reports and other pertinent IND data (including, but not limited to, Clinical Brochure 

  

					
	 	 	C-5	 	CONFIDENTIAL

	 	 
data, formulation and preclinical data, including toxicology findings) will be provided to Collaborator as they become available.

  
 In the event that Collaborator informs the
FDA of any serious or unexpected adverse events, Collaborator must notify the NCI at the same time. NCI will then notify the investigator(s) conducting studies under NCI-sponsored protocol. 
  
 Upon transfer to Collaborator of NCI Protocol #00-C-0050 (P-92).
Collaborator shall report all serious or unexpected adverse events to FDA in accordance with the reporting obligations of 21 CFR 312.32. All other adverse event reports received by Collaborator shall be reported to the FDA consistent with 21
CFR 312.32 and 312.33. 
  
 Add a new Article
4.4 as follows: 
  

	4.4	Annual Reports. NCI shall provide Collaborator a copy of the relevant portions of the Annual Report simultaneously with the submission of the Annual Report to the FDA.

  
 Amend Article 5 “Financial and Staffing
Obligations” as follows: 
  

	5.1	PHS and Collaborator Contributions. The contributions of the Parties, including personnel, services, property and payment schedules, if applicable, are set forth in Appendix
B. PHS shall not be obligated to perform any of the research specified herein or to take any other action required by this CRADA if the funding is not provided as set forth in Appendix B. PHS shall return excess funds to the Collaborator when it
sends its final fiscal report pursuant to Article 5.2, except for staffing support pursuant to Article 10.3. Collaborator acknowledges that the U.S. Government will have the authority to retain and expend any excess funds for up to one (1) year
subsequent to the expiration or unilateral termination of the CRADA to cover any costs incurred during the term of the CRADA in undertaking the work set forth in the RP. 

  

	5.2	Accounting Records. PHS shall maintain separate and distinct current accounts, records, and other evidence supporting all its obligations under this CRADA, and shall provide
the Collaborator a final fiscal report reflecting the use of Collaborator funds, technical progress, established goals and objectives pursuant to Article 4.2. 

  
 Amend Article 6 “Patent Applications” as follows: 
  

	6.2	Filing of Patent Applications. Each party shall be responsible for filing patent or other IP applications in a timely manner and at its own expense and after consultation
with the other Party. The Parties will consult and mutually determine a filing strategy for jointly-owned subject inventions. Either Party may elect not to file a patent or other IP application thereon in any particular country or countries,
provided it so advises the other Party ninew (90) days prior to the expiration of any applicable filing deadline, priority period, or statutory bar date, and hereby agrees to assign its IP right, title and interest in such country or countries to
the Subject Invention to the other Party and to cooperate in the preparation and filing of a patent or other IP applications. If trade secret information or Collaborator Confidential/Proprietary is essential to file a properly enabled patent
application. Collaborator will cooperate to provide equivalent information to file such application. 

  

					
	 	 	C-6	 	CONFIDENTIAL

	6.3	Patent Expenses. The expenses attendant to the filing or maintaining of patent or other IP applications generally shall be paid by the Party filing such application. If an
exclusive license to any Subject Invention is granted to the Collaborator, the Collaborator shall be responsible for all reasonable past and future out-of-pocket expenses in connection with the preparation, filing, prosecution and maintenance of any
applications claiming such exclusively-licensed inventions and any patents or other IP grants that may issue on such applications. The Collaborator may waive its exclusive license rights on any application, patent or other IP grant at any time, and
incur no subsequent compensation obligation for that application, patent or IP grant. 

  

	6.4	Prosecution of Intellectual Property Applications. Within one month of receipt or filing, each Party shall provide the other Party with copies of the applications and all
documents received from or filed with the relevant patent or other IP office in connection with the prosecution of such applications. Each Party shall also provide the other Party with the power to inspect and make copies of all documents retained
in the patent or other IP application files by the applicable patent or other IP office. Each Subject Invention made solely by PHS employees shall be owned by PHS.: excluding any PHS agrees to exclude from any patent application Collaborator trade
secret information or Collaborator Proprietary/Confidential Information. If such trade secret information or Collaborator Confidential/Proprietary is essential to file a properly enabled patent application. Collaborator will cooperate to provide
equivalent information to file such application. Where licensing is contemplated by the Collaborator, t The Parties agree to consult with each other with respect to the prosecution of applications for PHS Subject Inventions and joint Subject
Inventions. If the Parties agree that Collaborator shall file and prosecute IP applications on joint Subject Inventions, then Collaborator agrees to grant PHS an associate power of attorney (or its equivalent) on such EP applications.

  
 Amend Article 7
“Licensing” to read as follows: 
  

	7.1	Option for Commercialization License. With respect to Government IP rights to any Subject Invention not made solely by the Collaborator’s employees for which a patent or
other IP application is filed, PHS hereby grants to the Collaborator an exclusive option to elect an exclusive or nonexclusive commercialization license, which is substantially in the form of the appropriate model PHS license agreement. This option
does not apply to Subject Inventions conceived prior to the effective date of this CRADA that are reduced to practice under this CRADA, if prior to that reduction to practice, PHS has filed a patent application on the invention and has licensed it
or offered to license it to a third party. To the best of NCI’s knowledge after due inquiry on the date that NCI signed this CRADA no such Subject Invention exists. In the event that it is later determined that any such Subject Invention does
exist. Collaborator shall be granted an option to a nonexclusive license for any such Subject Invention licensed to a Third Party on a nonexclusive basis. The terms of the license will fairly reflect the nature of the invention, the relative
contributions of the Parties to the invention and the CRADA, the risks incurred by the Collaborator and the costs of subsequent research and development needed to bring the invention to the marketplace. The field of use of the license will be
commensurate with the scope of the RP. 

  

					
	 	 	C-7	 	CONFIDENTIAL

	7.2	Exercise of License Option. The option of Article 7.1 must be exercised by written notice mailed within three (3) months after either (i) Collaborator receives written notice from
PHS that the patent or other IP application has been filed; or (ii) the date Collaborator files such IP application. Exercise of this option by the Collaborator initiates a negotiation period that expires nine (9) months after the exercise of the
option. If the last proposal by the Collaborator has not been responded to in writing by PHS within this nine (9) month period, the negotiation period shall be extended to expire one (1) month after PHS so responds, during which month the
Collaborator may accept in writing the final license proposal of PHS. In the absence of such acceptance, or an extension of the time limits by PHS, PHS will be free to license such DP rights to others. In the event that the Collaborator elects the
option for an exclusive license, but no such license is executed during the negotiation period, PHS agrees not to make an offer for an exclusive license on more favorable terms to a third party for a period of six (6) months without first offering
Collaborator those more favorable terms. These times may be extended at the sole discretion of PHS upon good cause shown in writing by the Collaborator. 

  

	7.5	Third Party License. Pursuant to 15 U.S.C. 3710a(b)(l)(B), if PHS grants an exclusive license to a Subject Invention made wholly by PHS employees or jointly with a Collaborator
under this CRADA, the Government shall retain the right to require the Collaborator to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to use the invention in Collaborator’s licensed field of use on
terms that are reasonable under the circumstances; or if the Collaborator fails to grant such a license, to grant the license itself. The exercise of such rights by the Government shall only be in exceptional circumstances and only if the Government
determines (i) the action is necessary to meet health or safety needs that are not reasonably satisfied by Collaborator, (ii) the action is necessary to meet requirements for public use specified by Federal regulations, and such requirements are not
reasonably satisfied by the Collaborator; or (iii) the Collaborator has failed to comply with an agreement containing provisions described in 15 U.S.C. 3710a(c)(4)(B). The determination made by the Government under this Article is subject to
administrative appeal and judicial review under 35 U.S.C. 203(2). Subject to Article 7.4 herein, the Collaborator shall retain ownership in any intellectual property to which the Collaborator has title prior to this CRADA. or which is outside the
workscope of this CRADA. 

  
 Amend
Article 8 “ Proprietary Rights and Publication” to read as follows: 
  

	8.1	Right of Access. PHS and the Collaborator agree to exchange all Subject Data and Research Materials produced in the course of research under this CRADA whether developed solely by
PHS. jointly with Collaborator or solely by the Collaborator. Research Materials will be shared equally by the Parties to the CRADA unless other disposition is agreed to by the Parties. All Parties to this CRADA will be free to utilize Subject Data
and Research Materials for their own purposes, consistent with their obligations under this CRADA. 

  

	8.3	 Dissemination of Subject Data and Research Materials. To the extent permitted by law, the Collaborator and PHS agree to use reasonable efforts to keep
Subject Data and Research Materials confidential until published or until corresponding patent applications are filed. Any information that would identify human subjects of research or patients will always be maintained confidentially. To the extent
permitted by law and subject to the other provisions of Article 8. 

  

					
	 	 	C-8	 	CONFIDENTIAL

	 	 
the Collaborator shall have the exclusive right to use any and all CRADA Subject Data in and for any regulatory filing by or on behalf of Collaborator,
except that PHS shall have the exclusive right to use Subject Data for that purpose, and authorize others to do so, if the CRADA is terminated or if Collaborator abandons its commercialization efforts. Collaborator acknowledges the basic research
mission of the PHS, and agrees that after publication, PHS may make unpatented research materials arising out of this CRADA available to third parties for further research. 

  
 Modify Article 8.4 as follows: 
  

	8.4.	Proprietary/Confidential Information. Each Party agrees to limit its disclosure of Proprietary/Confidential Information to the amount necessary to carry out the Research Plan
of this CRADA, and shall place a confidentiality notice on all such information. Confidential oral communications shall be reduced to writing within 30 days by the disclosing Party. Each Party receiving Proprietary/Confidential Information agrees
that any information so designated shall be used by it only for the purposes described in the attached Research Plan. Any Party may object to the designation of information as Proprietary/Confidential Information by another Party. Subject Data and
Research Materials developed solely by the Collaborator may be designated as Proprietary/Confidential Information when they are wholly separable from the Subject Data and Research Materials developed jointly with PHS investigators, and advance
designation of such data and material categories is set forth in the RP. The exchange of other confidential information, e.g. patient-identifying data Identifiable Private Information, should be similarly limited and treated shall be subject to the
terms of Article 8.10. Jointly developed Subject Data and Research Material derived from the Research Plan may be disclosed by Collaborator to a third party under a confidentiality agreement for the purpose of possible sublicensing pursuant to the
Licensing Agreement and subject to Article 8.7. 

  

	8.6	Duration of Confidentiality Obligation. The obligation to maintain the confidentiality of Proprietary/Confidential Information shall expire at the earlier of the date when
the information is no longer Proprietary Information as defined in Article 2.7 or three, (3) five (5) years after the expiration or termination date of this CRADA. The Collaborator may request an extension to this term when necessary to protect
Proprietary/Confidential Information relating to products not yet commercialized. 

  

	8.7	Publication. The Parties are encouraged to make publicly available the results of their research. Before either Party submits a paper or abstract for publication or otherwise
intends to publicly disclose information about a Subject Invention, Subject Data or Research Materials, the other Party shall be provided thirty (30) days to review the proposed publication or disclosure to assure that Proprietary/Confidential
Information is protected. The other party may request such publication to be revised if it discloses Proprietary/Confidential information. The publication or other disclosure shall be delayed for up to thirty (30) sixty (60) additional days upon
written request by any Party as necessary to preserve U.S. or foreign patent or other IP rights. If trade secret information or Collaborator Proprietary/Confidential is essential to publish or otherwise publicly disclose as outlined above.
Collaborator will cooperate to provide equivalent information to file such application. 

  

					
	 	 	C-9	 	CONFIDENTIAL

 Add a new Article 8.8 as follows: 
  

	8.8	Extramural Research and Data. In pursuing the development of Agent pursuant to this CRADA, NIH may will utilize extramural investigators for part or all of the
completion of this Research Plan. through Funding Agreements. Participation by extermural investigators shall DC determined after competitive solicitation and review of study protocols by NIH. However, said extramural investigators are not Parties
to this CRADA, and this CRADA does not address rights to intellectual property created by such investigators. Nonetheless: 

  

	 	a.	To the extent permitted by law and subject to the other provisions of Article 8 of this CRADA, NIH shall maintain all IND, Clinical Data and Results, and Raw Data in
NIH’s Possession and Control as Proprietary and CONFIDENTIAL, and make them data related to NCI Protocol 00-C-0050 (P-92) available exclusively to the Collaborator, for its own use and for use in obtaining FDA approval for the commercial
marketing of Subject Inventions and Agent products. Accordingly, said data shall not be transferable to any third party by Collaborator without the written permission of the NCI, which will not be unreasonably withheld. 

  

	 	b.	NIH shall not execute a Funding Agreement for preclinical studies or clinical trials for the development of Agent unless the extramural investigator agrees to confidentiality
provisions at least as restrictive as provided in this CRADA and to the Collaborator’s exclusive use of data, in accordance with Article 8.8 (a), for its own use and for use in obtaining FDA approval for the commercial marketing of Agent.

  

	 	c.	To the extent permitted by law, Clinical Data and Results and Raw Data will be made available exclusively to Collaborator, the NCI and the FDA, as appropriate and for use in
obtaining pharmaceutic regulatory approval for the commercial marketing of Agent. 

  

	 	d.	Until NCI Protocol #00-C-0050 (P-92) is transferred to Collaborator, in In seeking direct access to Clinical Data and Results and Raw Data or any other information that is in
the possession of extramural investigators under a Funding Agreement working with Agent under the sponsorship of NCI, Collaborator shall first contact the Regulatory Affairs Branch, (RAB) NCI [telephone: 301-496-7912]. Subsequent to authorization by
RAB, Collaborator may directly contact the extramural investigators. Costs associated with providing Clinical Data and Results or Raw Data to Collaborator in customized formats shall be borne by Collaborator. 

  

	 	e.	Collaborator’s exclusive access under subsection (a) above to Clinical Data and Results and Raw Data in NIH’s Possession and Control is dependent, however, upon
Collaborator’s continued development and commercialization of the technology. In the event that Collaborator discontinues development or commercialization of the technology without the transfer of its development efforts to another party, NCI
retains the right to make the Clinical Data and Results and Raw Data in NIH’s Possession and Control available to another collaborator. 

  

					
	 	 	C-10	 	CONFIDENTIAL

 Add a new Article 8.9 “Retention and Disposition of Patient Samples” as
follows: 
  

	8.9	Retention and Disposition of Patient Samples. The parties anticipate that certain patients enrolled in the clinical trial performed under this CRADA will be removed from the study
for any number of reasons including the following examples: 

  
 1. Patient unable to obtain a complete response with chemotherapy 
 2. Tumor returns after chemotherapy while
waiting to start vaccine 
 3. Tumor returns after vaccinations are completed 
 4. Patient is unable to tolerate the treatment 
  
 Collaborator agrees that in the event a patient is removed from the study performed under this CRADA for any reason, the patient shall be free to enter
any other trial and their biopsies, hybridomas and associated clinical or biopsy data needed for such a new trial will be transferred for use in that study. Collaborator will cooperate in transferring all required information upon receipt of written
patient authorization to such transfer to the specified recipient. Collaborator will not use patient samples or derivatives thereof for purposes not specified in this CRADA. 
  
 Add a new Article 8.10 “Access Review and Receipt of Identifiable Private Information” as
follows: 
  

	8.10	Access, Review and Receipt of Identifiable Private Information. Collaborator access to and review of Identifiable Private Information shall be only for on-site quality
auditing. Collaborator will receive Identifiable Private Information only for purposes of satisfying FDA or other health authorities’ reporting requirements, and for internal research purposes directly related to obtaining regulatory approval
of Agent. Collaborator is prohibited from access, review, receipt, or use of such information for other purposes. All IRB approved protocol and informed consent documents related to this research project will clearly describe this practice. If the
Collaborator will have access to Identifiable Private Information, the protocol and the informed consent must clearly state (i) the existence of the Collaborator; (ii) the Collaborator’s access to Identifiable Private Information, if
any, and (iii) the extent to which confidentiality will be maintained . For clinical protocol involving a third party, the other party’s access, review, receipt, or use of Identifiable Private Information shall be subject to the same
limitations as described in this Article 8.10. 

  
 Add a new Article 8.11 “Multi-Party Data” as follows: 
  

	8.11	“Multi-ParryData” means clinical data which is collected from clinical studies sponsored by NCI for combinations of proprietary investigational agents
supplied by more than one Collaborator. 

  
 For
clinical protocol(s) where Agent is used in combination with another proprietary investigational agent which is the subject of another Clinical Trials Agreement or Cooperative Research and Development Agreement, the access to and use of data by
Collaborator and party supplying other agent (hereinafter referred to as “Other Party”) shall be as follows (data pertaining to such combination use shall hereinafter be referred to as “Multi-Party Data.’”): 
  

	 	i.	            NCI must provide all parties with written notice regarding the existence 

  

					
	 	 	C-11	 	CONFIDENTIAL

	 	 
and nature of any agreements governing their collaboration with NIH. the design of proposed combination protocols), and the existence of any obligations
which would tend to restrict NCI’s participation in proposed combination protocols. 

  

	 	ii.	Collaborator shall agree to permit use of the Multi-Party Data from these clinical trials by Other Party to the extent necessary to allow Other Party to develop, obtain regulatory
approval of. or commercialize its own proprietary investigational agent, provided Other Party permits Collaborator similar, reciprocal rights to use Multi-Party Data. 

  

	 	iii.	Any Party having the right to use the Multi-Party Data from these trials must agree in writing prior to the commencement of the trials that it will use the Multi-Party Data solely
for development, regulatory approval, and commercialization of its own proprietary investigational agent(s). 

  
 Amend Article 10 “Termination” as follows: 
  

	10.2	Unilateral Termination. Either PHS or the Collaborator may unilaterally terminate this entire CRADA at any time by giving written notice at least thirty (30) sixty (60) days
prior to the desired termination date, and any rights accrued in property, patents or other IP rights shall be disposed of as provided in paragraph 10.1, except that PHS may, at its option, retain funds transferred to PHS prior to unilateral
termination by Collaborator for use in completing the Research Plan solely or with another partner. However, in the event of unilateral termination by Collaborator. Collaborator’s obligation under Article 3.8 will survive termination to the
extent reasonably necessary to complete approved clinical studies under mutually agreed upon protocol. If Collaborator elects to terminate its development of Agent without the transfer of its development efforts to support a level of production
equivalent to that which was ongoing at the time of termination, and NCI elects to continue its development of Agent, then Collaborator agrees to maintain its IND. to provide a letter of cross-reference to Collaborator’s IND. and to provide
financial support for personnel, reagents, supplies, and equipment necessary to transfer back to NCI all vaccine production, including, but not limited to all relevant biological and immunological assays. Such obligation shall last until either a
date on which vaccine production and related assays are fully transferred back to NCI or one two year after the notification from Collaborator to NCI that Collaborator elects to terminate its development of Agent, whichever comes first.
Notwithstanding the foregoing, if NCI has executed an agreement with anew collaborator or third party to be involved in development of Agent. Collaborator’s funding obligations shall be terminated immediately. 

  

	10.3	 Staffing. If this CRADA is mutually or unilaterally terminated by the Collaborator prior to its expiration, funds will nevertheless remain available
to PHS for continuing any staffing commitment made by the Collaborator pursuant to Article 5.1 above and Appendix B, if 

  

					
	 	 	C-12	 	CONFIDENTIAL

	 	 
applicable, for a period of six (0) months one year after such termination. If there are insufficient funds to cover this expense, the Collaborator agrees to
pay the difference. 

  
 Add
a new Article 10.6 as follows: 
  

	10.6	Research License and Alternative Sources of Supply in the Event Collaborator Terminates Development of Agent 

  

	 	a.	Collaborator hereby grants to NCI a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States any Subject
Invention which Collaborator may have or obtain on Agent, its manufacture, or on the process for use of Agent, throughout the world, for medical research purposes, including those related to or connected with the therapy of cancer; but this license
shall become effective only if and when Collaborator terminates its development of Agent without the transfer of its development efforts to another party, and NCI elects to continue the development of Agent. 

  

	 	a.	If Collaborator elects to terminate its development of Agent without the transfer of its development efforts to another party, and NCI elects to continue its development of Agent,
then Collaborator will: 

  

	 	(i)	allow NCI to purchase at cost said Agent from Collaborator inventory; or 

  

	 	(ii)	arrange for an independent contractor to manufacture and provide for NCI purchase of said agent at cost; or 

  

	 	(i)	provide to NCI all information necessary to allow NCI to contract and manufacture said Agent independent of Collaborator; or 

  

	 	(ii)	arrange for alternative and cost-effective method of Agent production 

  
 for use in preclinical studies and clinical trials. Such obligation shall last until either a date on which an alternate source of equivalent materials,
acceptable to NCI, can be obtained by NCI, or one year after the date of notification from Collaborator to NCI that Collaborator elects to terminate its development of Agent, whichever comes first. 
  
 Modify the first sentence in Article 12.3 as follows:

  
 The Collaborator agrees to hold the U.S. Government harmless
and to indemnify the Government for all liabilities, demands, damages, expenses and losses arising out of the use by the Collaborator for any purpose of the Subject Data, additional Clinical Data and Results and Raw Data in NTH’s Possession and
Control. Research Materials and/or Subject Inventions produced in whole or part by PHS employees under this CRADA, unless due to the negligence or willful misconduct of PHS, its employees, or agents. 
  

					
	 	 	C-13	 	CONFIDENTIAL

 Modify Article 13.1 as follows: 
  

	13.1	Governing Law. The construction, validity, performance and effect of this CRADA shall be governed by Federal law, as applied by the Federal Courts in the District of
Columbia. Federal law and regulations will preempt any conflicting or inconsistent provisions in this CRADA. NCI and Collaborator, if Collaborator is sponsoring trials at the NTH under this CRADA, shall comply with all Department of Health
and Human Services regulations relating to Human Subject use. and all Public Health Service policies relating to the use and care of laboratory animals. 

  
 Add the following to the beginning of Article 13.2 as follows: 
  

	13.2	The Parties hereby modify their rights under the following prior agreements: 

  

Confidential Disclosure Agreement: 
  
 # 2-02244-01 
 Subject: “Discussions for
the entering into of a Cooperative Research & Development Agreement (“CRADA”) for the development and production of idiotvpe vaccines against B-cell lymphoma.” 
 Executed: September 20, 2000. 
  
 and the Parties agree that the information provided thereunder is now governed, retroactive to the date of the LOI (January. 09. 2001). by the
confidentiality and intellectual Property terms of this CRADA. 
  
 Add a new Article 13.13 as follows: 
  

	13.13	FDA Meetings. All meetings with FDA concerning clinical studies for the development of Agent within the scope of the CRADA Research Plan will be discussed by Collaborator and
NCI in advance and will be held on mutually agreed upon dates. Collaborator reserves the right to set jointly with NCI the agenda for any such meeting. 

  
 Modify Article 13.8 “Notices” as follows: 
  

	13.8	Notices. All notices pertaining to or required by this CRADA shall be in writing and shall be signed by an authorized representative and shall be delivered by hand or sent by
certified mail, return receipt requested, or by recognized national overnight carrier, with postage prepaid, to the addresses indicated on the signature page for each Party. Notices regarding the exercise of license options shall be made pursuant to
Article 7.2. Any Party may change such address by notice given to the other Party in the manner set forth above. 

  

					
	 	 	C-14	 	CONFIDENTIAL

 Modify Article 13.9 “Independent Contractors” as follows: 

 

	13.9	Independent Contractors. The relationship of the Parties to this CRADA is that of independent contractors and not agents of each other or joint venturers or partners. Each
Party shall maintain sole and exclusive control over its personnel and operations. Collaborator employees who will be working at PHS facilities may be asked to sign a Guest Researcher or Special Volunteer Agreement appropriately modified in view of
the terms of this CRADA. If Collaborator elects to perform any portion of the Research Plan through a contractor or consultant. Collaborator agrees to incorporate into such contracts all provisions necessary to ensure that the work of such
contractors or consultants is governed by the terms of the CRADA. In addition Collaborator will have incorporated in any agreement with any contractor or consultant contemplated hereby a provision for the assignment of inventions of the contractor
or consultant to the Collaborator: such inventions shall be deemed Subject Inventions of the Collaborator. Some of the studies of the Research Plan for this CRADA may be conducted by a contractor working on behalf of the NIH. It is the intent of the
NIH that the contractor not perform any duties likely to generate intellectual property. However, the Collaborator is aware that pursuant to the Bayh-Dole Act (codified art 35 USC, Chapter 18). the contractor may elect title to any inventions it
makes in the performance of its contract duties. Such contractor inventions are not subject to the terms of this CRADA. 

  
 Amend Article 14.2 Survivability by including Articles 4.3 (Adverse Drug Experience Reporting) and 10.6 (Research License and Alternative Sources
of Supply in the Event that Collaborator Terminates Development of Agent) and the last sentence of Article 10.2 (regarding drug supply in the event of collaborator’s unilateral termination) as provisions that will survive termination of
this CRADA. 
  
 14.2 Survivability. The provisions of Articles 4.2. 4.3.
5-8. Article 10.2. 10.3-10.5.10.6. 11.1, 12.2-12.4, 13.1, 13.10 and 14.2 shall survive the termination of this CRADA. 
  

					
	 	 	C-15	 	CONFIDENTIAL

  
 APPENDIX D 
  
 LETTER OF INTENT 
  
 AND 
  
 EXTENSION TO LETTER OF INTENT 
  
 CRADA #01030 
  

							
	

	 	 DEPARTMENT OF HEALTH AND HUMAN SERVICES
	 	 Public Health Service

			
	 	 	December 14, 2000	 	 National Institutes of Health
 National Cancer
Institute
 Technology Development and
 Commercialization
Branch
 NCI-FCRDC
 P.O. Box B, FVC/502
 Frederick, MD 21702-1201

			
	 	 	 Dr. Christopher Kyriakides
 Chief Executive Officer
 Biovest International, Inc.
 8500 Evergreen Blvd.
 Coon Rapids, Minnesota 55433
	 	 Overnight Delivery Address
 1003 West Seventh
Street
 Fairview Center, Suite 502
 Frederick; MD
21702
  
 301-846-5465
 301-846-6820 FAX

	 	 	 REFERENCE:
	 	 
	 	 	 Proposed Cooperative Research and Development Agreement (CRADA)
	 	 
	 	 	 CRADA #: 01030
	 	 
	 	 	 NIH Principal Investigator:
	 	 Larry W. Kwak, M.D., Ph.D.
	 	 
	 	 	 Collaborator Investigator:
	 	 Dr. Christopher Kyriakides
	 	 
	 	 	 Development of Idiotype Tumor Vaccines for Treatment of B-cell Lymphomas
	 	 

  
 ***Letter of
Intent*** 
  
 Dear Dr. Kyriakides, 
  
 “ It is my understanding that a cooperative research and development project between the
parties referenced below is being considered. Accordingly, until a formal Collaborative Research and Development Agreement (CRADA) is reviewed by the CRADA Subcommittee and approved by the Director, National Cancer Institute (NCI), this letter is
offered to permitjoint research to commence. However, in the case of human clinical trials which are a part of the subject CRADA, the Parties agree that all such trials which may begin prior to the execution of the formal CRADA Agreement shall be
preceded by the appropriate US Food and Drug Administration IND approval (or international equivalents thereof). 
  
 It is acknowledged by the parties below that cooperative research pursuant to the Research Plan, attached as Appendix A, will be conducted informally by the NCI Principal
Investigator(s) and Collaborator pending formal approval of this CRADA. It is further acknowledged that patentable inventions may be made by NCI employees and employees of the Collaborator. Pursuant to its authority under the Federal Technology
Transfer Act of 1986, NCI agrees that should this CRADA be approved, it will have retroactive effect to the date that the last party has executed this Letter for any inventions that may be made under this Research Plan. NCI further agrees that
should this CRADA be approved it will have retroactive effect to the date that the last party has executed this Letter for confidentiality obligations specified in the NIH Model CRADA. The NIH Model CRADA provisions for the protection of proprietary
information are incorporated in this letter of intent by reference and are considered controlling during the period of informal joint research. These provisions include, but are not limited to, Articles 2.7 and 8.1-8.7. The NIH Model CRADA is
attached as Appendix B. 
  
 You understand, however, that this Letter is not a
commitment on the part of either party to enter into a CRADA. Further, this Letter is effective for a term of six months. The six month term may 

  

 
be extended, provided the CRADA is under active negotiation and the collaborative research is continuing. Assuming the necessary approvals are forthcoming,
we look forward to a successful collaboration. 
  

	
	Sincerely,
	
	 /s/ Kathleen Sybert

	 Kathleen Sybert, Ph.D.

	 Chief, TDCB, NCI

  
 ACCEPTED AND AGREED TO:  
  

					
	 National Cancer Institute
	 	 	 	 Biovest International, Inc.

			
	 /s/ Alan S. Rabson
	 	 	 	 /s/ Dr. Christopher Kyriakides

	Alan S. Rabson, M.D.	 	 	 	Dr. Christopher Kyriakides
	 Deputy Director, NCI
	 	 	 	 Chief Executive Officer

			
	 Date 12/22/00
	 	 	 	 Date 1/9/01

  

					
	

	 	DEPARTMENT OF HEALTH & HUMAN SERVICES                     .	  	Public Health Service
			
	 	 	 	  	 National Institutes of Health
 National Cancer Institute
 Technology Transfer Branch
 NCI-Frederick
 PO BOX B
 Fairview Center, Suite 502
 Frederick, MD 21702-1201
 (301) 846-5465
 (301) 846-6820 fax

  
 Dr. Christopher Kyriakides 

Chief Executive Officer 
 Biovest International, Inc. 
 8500 Evergreen Blvd. 
 Coon Rapids, Minnesota 55433 
  

	Re:	Proposed Cooperative Research and Development Agreement (CRADA) 

  
 Proposed CRADA #: 01030 
 NCI Principal Investigator: Larry W. Kwak, M.D.,
Ph.D. 
 Collaborator Investigator: Christopher Kyriakides, M.D. 
 Title: Development of Hybridoma-based Idiotypic Tumor Vaccines for the Treatment of Follicular B-cell Lymphoma. 
  
 Dear Dr. Kriakides, 
  
 It is my understanding that a cooperative research and development project between the parties referenced below is being considered. Accordingly, until a formal Collaborative Research and Development Agreement (CRADA)
is reviewed by the CRADA Subcommittee and approved by the Director, National Cancer Institute (NCI), the attached Letter of Intent and its associated appendices was executed to permit joint research to commence. At this time both parties agree to
extend the term of the Letter of Intent an additional 3 months. Upon signature of all parties to this extension of the Letter of Intent, the new expiration date of the Letter of Intent is October 09, 2001. All terms and conditions of the original
Letter of Intent shall be in force through the time period covered under this extension. 
  
 You understand, however, that the Letter of Intent is not a commitment on the part of either party to enter into a CRADA. Assuming the necessary approvals are forthcoming, we look forward to a successful
collaboration. 
  

	
	 Sincerely,

	
	 /s/ Kathleen K. Sybert

	 Kathleen K. Sybert, Ph.D., J.D.

	 Chief, TTB, NCI

  
 AUTHORIZED SIGNATURES
ON NEXT PAGE 
  

 Proposed CRADA #: 01030                 
Letter of Intent Extension 
 NCI Principal Investigator: Larry W. Kwak, M.D., Ph.D. 
 Collaborator Investigator: Christopher Kyriakides, M.D. 
 Title: Development of Hybridoma-based Idiotypic Tumor Vaccines
for the Treatment of Follicular B-cell Lymphoma. 
  
 ACCEPTED AND AGREED TO: 
  

					
	National Cancer Institute	 	 	 	Biovest International, Inc.
			
	 /s/ Alan Rabson
	 	 	 	 /s/ Christopher Kyriakides

	 Alan Rabson, M.D.
	 	 	 	 Christopher Kyriakides, M.D.

	 Deputy Director, NCI
	 	 	 	 Chief Executive Officer, Biovest

			
	 6/14/01
	 	 	 	 6/25/01

	 Date
	 	 	 	 Date

  
 Attachments: 
  
 Original Letter of Intent and Associated Appendices (A and B)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00078-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00078-of-00352.parquet"}]]